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Abstract 
 
Epigenetics and its key role in gene expression have become increasingly important in 
cancer research. Histone proteins play an important role in gene expression control through 
modifications like acetylation, phosphorylation and methylation. Histone deacetylases (HDAC) 
can regulate expression levels via acetylation of lysine residues of histone proteins.  
Inhibitors of these HDAC have been associated with cancer and some are 
commercialized as anticancer drugs like SAHA (Vorinostat) and Belinostat (PXD101). These 
histone deacetylases inhibitors (HDACi) are known to have several effects in altered or malignant 
cells such as accumulation of acetylated proteins, proliferation arrest, cell cycle arrest, and 
induction of apoptosis.  
The purpose of this work was to synthesize new HDACi with anticancer effects. For this, 
several analogues were synthesized inspired in the structures of SAHA and Belinostat where key 
aspects of the HDACi structures were altered. Breast cancer (MCF-7) and lung cancer (H460) 
cell lines were used in order to evaluate the newly synthesized compounds as antitumour agents.  
Overall, 30 compounds were successfully synthesized and were used in further analysis 
in cancer cell lines.  
Results showed that the synthesized compound N-hydroxy-N'-(4-
iodophenyl)octanediamide (16c) is a putative new HDACi with anticancer effects, exhibiting an 
cytotoxic effect in both cancer cell lines tested and preliminary data suggested that it induced the 
same cell death mechanisms as the previously described for SAHA. 
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Resumo 
 
A epigenética e o seu papel na regulação génica têm vindo a tornar-se muito importantes 
na investigação em oncologia. As histonas exercem uma função fundamental na regulação dos 
genes através de modificações como a acetilação, fosforilação e metilação. As deacetilases de 
histonas (HDAC) regulam os níveis de expressão através da acetilação de lisinas presentes em 
histonas.  
Os inibidores destas enzimas têm sido usados na terapia do cancro e alguns são 
comercializados como fármacos anticancerígenos tais como o SAHA (Vorinostat) e o Belinostat 
(PXD101). Estes inibidores de deacetilases de histonas (HDACi) têm como efeitos conhecidos a 
acumulação de proteínas acetiladas, paragem da proliferação, paragem do ciclo celular e a 
indução da apoptose em células alteradas ou malignas.  
O objetivo deste trabalho foi a síntese de novos HDACi com efeitos anticancerígenos. 
Para tal, vários compostos análogos foram sintetizados baseados nas estruturas dos fármacos 
SAHA e Belinostat onde aspetos importantes da estrutura foram alterados. Linhas celulares de 
cancro de mama (MCF-7) e de pulmão (H460) foram usadas para avaliar os compostos 
sintetizados como agentes anticancerígenos.  
No total, foram sintetizados com sucesso e posteriormente testados em linhas celulares 
cancerígenas 30 compostos.  
Os resultados obtidos mostraram que o composto sintetizado N-hidroxi-N'-(4-
iodofenil)octanodiamida  (16c), revelou um efeito anticancerígeno maior do que o provocado pelo 
SAHA em ambas as linhas celulares testadas e resultados preliminares sugerem que induz 
mecanismos de morte celular similares aos descritos previamente para o SAHA.   
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I. INTRODUCTION 
 
I.1 Cancer and Epigenetics 
 
Cancer is one of the leading causes of mortality worldwide, with approximately 8.2 million 
cancer related deaths in 2012. In the next 2 decades, the number of new cases is expected to 
increase by approximately 70%. The most common causes of cancer death are lung, liver, 
stomach, colorectal, breast and oesophageal cancer1. (Figure I.1).  
Treatment options against cancer comprise surgery, chemotherapy and radiotherapy and 
an early detection, accurate diagnosis, and effective treatment are crucial for increasing cancer 
survival1. 
 
Figure I.1 - Most common causes of cancer death. Data obtained from the World Health Organization1. 
 
Cancer is characterized by cells with rapid and abnormal growth which are able to invade 
adjacent parts of the body and spread to other organs, a process called metastasizing. Cancerous 
cells are the result of genetic and genomic alterations such as point mutations, deletions and 
translocations2. Genetic alterations can ultimately lead to the activation of oncogenes and 
inactivation of tumor-suppressor genes. More recently, cancer development has been correlated 
not only with genetic alterations but also with epigenetic modifications that contribute to disease 
progression3. Genetics is concerned with the information transmitted on the basis of gene 
sequence whereas epigenetics studies the inheritance of information based on gene-expression 
levels that do not involve changes in the underlying DNA sequence4.  
34%
16%15%
15%
11%
9%
Lung  (1.59 million deaths)
Liver (745 thousand deaths)
Stomach (723 thousand deaths)
Colorectal (694 thousand deaths)
Breast (521 thousand deaths)
Oesophageal  (400 thousand
deaths)
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In recent years, numerous studies described extensive reprogramming of epigenetic 
machinery components in cancer, including DNA methylation and histone modifications. A first 
indication that epigenetic modifications such as histone acetylation may be strongly involved in 
cancer onset and progression came from a study demonstrating a global loss of monoacetylation 
and trimethylation on histone H4 in cancer cells5. Other similar studies have shown that epigenetic 
enzymes are often dysregulated in human tumors4.  
Identification of these enzymes has driven the rapid development of small-molecule 
inhibitors that target the cancer epigenome. Within this purpose, histone deacetylases inhibitors 
(HDACi) were studied as potential antitumor agents. There are now several HDACi 
commercialized as anticancer medicines such as suberoylanilide hydroxamic acid (SAHA) and 
Belinostat (PXD101), approved for the treatment of specific types of cancer (see section I.4.2).  
 
I.2 Histone Regulation and Acetylation 
 
Eukaryotic organisms have their genetic information packaged inside the cell nucleus. 
This arrangement is mediated by histones which are small basic proteins rich in lysine and 
arginine residues that strongly adhere to negatively-charged DNA and form complexes called 
nucleosomes6. Nucleosomes are the basic units of chromatin and are formed by an octamer of 
the four core histones (H3, H4, H2A, H2B) around which DNA is wrapped 7.  
The amino acid tails of core histones can be subjected to several post-translational 
modifications like acetylation, methylation and phosphorylation, and this facilitates processes 
including transcription, replication and repair7,8. While the base sequence of DNA provides the 
fundamental code for proteins, post-translational modifications (PTM´s) of histone proteins play a 
major role in the control of gene transcription 9. These epigenetic modifications can lead to 
changes in function and/or regulation of several proteins including histones, without altering their 
primary sequences.  
Histone acetylation is the modification most widely studied. In general, high levels of 
acetylation (hyperacetylation) are correlated with higher transcriptional activity and a more open 
chromatin conformation, whereas low levels of acetylation (hypoacetylation) cause chromatin 
condensation leading mainly to transcriptional suppression. 
Histone acetylation levels are mediated by the opposing actions of two different enzymes: 
Histone acetyl-transferases (HATs) that are responsible for transferring acetyl groups to lysine 
residues in histones N-terminal tails and histone deacetylases (HDACs) that remove the acetyl 
group 7,10. (Figure I.2)  
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I.3 Histone Deacetylase (HDAC)  
 
To date, 18 mammalian HDAC enzymes have been identified and are classified based 
on their homology with yeast transcriptional regulators11. These enzymes are divided into four 
different classes: classes I, II and IV, from the Zinc-dependent family (also called classical), and 
class III, which is a NAD +  (Nicotinamide adenine dinucleotide) dependent family (also called 
SIRT-sirtuins) 10. Concerning the Zinc-dependent family of HDAC enzymes (Table I.1), class I 
contains HDAC1, 2, 3, and 8 and shares homology with the yeast transcriptional regulator RDP3. 
The class II enzymes share homology with the yeast HDAC1 and are subdivided into class IIa, 
consisting of HDAC4, 5, 7, and 9, and class IIb, containing HDAC6 and 10. Class IIb differs 
structurally by containing two catalytic sites. HDAC11 shares characteristics with both class I and 
class II HDACs, so it is included in class IV12. Concerning the NAD + dependent family (Table 
I.1), class III contains seven proteins (SIRT1 - 7) that differ in cellular localization, activity, and 
function13. 
 
 
 
  
Figure I.2-  Histone Acetylation - Acetylation of lysine residues (mediated by HATs) will neutralize the 
histone positive charge and weakening its interaction with DNA. Previously tightly wrapped DNA around 
the histone will be more loose and more accessible to several processes like transcription, replication, etc. 
By removing acetyl groups, HDACs will have the opposing action. Adapted from D.Pons et al44.  
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Table I.1 - Classification of Zinc dependent family of HDAC enzymes.  
       CLASSES  HDAC ENZYME LOCALIZATION 
CLASS I HDAC1 Nucleus 
HDAC2 Nucleus 
HDAC3 Nucleus 
HDAC8 Nucleus/Cytoplasm 
CLASS IIa HDAC4 Nucleus/Cytoplasm 
HDAC5 Nucleus/Cytoplasm 
HDAC7 Nucleus/Cytoplasm 
HDAC9 Nucleus/Cytoplasm 
CLASS IIb HDAC6 Cytoplasm 
HDAC10 Cytoplasm 
CLASS III SIRT1 Nucleus 
 SIRT2 Cytoplasm 
 SIRT3 Nucleus/Mitochondria 
 SIRT4 Mitochondria 
 SIRT5 Mitochondria 
 SIRT6 Nucleus 
 SIRT7 Nucleus 
CLASS IV HDAC11 Nucleus/Cytoplasm 
   
HDAC enzymes are predominantly in the cell nucleus in order to exert their function. 
However, some HDAC can shuttle between the nucleus and the cytoplasm11.  
I.4 HDAC inhibitors (HDACi) 
 
Over the years, many different types of HDAC inhibitors (HDACi) have been developed, 
ranging from simple structures like butyrate to more complex structures such as SAHA or 
romidepsin. HDACi can be categorised based on their structure: hydroxamic acids, cyclic 
peptides, benzamides, and short-chain fatty acids (Table I.2).  
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Table I.2 -  HDAC inhibitors categories, structures and information about approval status as anticancer 
drugs. 
 
HDAC inhibitor Structure 
Approval status as 
anticancer drug 
(commercial name/brand) 
Hydroxamic 
acids Trichostatin A 
(TSA) 
 
 
- 
SAHA 
(Vorinostat) 
 
FDA Approved 2006 
(Zolinza) 
Belinostat  
(PXD101) 
 
FDA Approved 2014 
(BELEODAQ) 
Panobinostat 
(LBH589) 
 
FDA Approved 2015 
(FARYDAK) 
Givinostat 
(ITF2357) 
 
 
Undergoing clinical trials 
 
Cyclic 
Peptide 
Depsipeptide 
(romidepsin) 
 
FDA Approved 2009 
(ISTODAX) 
Benzamides Entinostat (MS-
275) 
 
Undergoing clinical trials 
Mocetinostat 
(MGCD0103) 
 
 
Undergoing clinical trials 
Fatty acids Sodium Butyrate 
 
- 
Valproic acid 
(VPA) 
 
 
- 
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The first proposed HDACi were short chain fatty acids, like sodium butyrate, but these 
were shown to be less effective in comparison with inhibitors of the other categories. Trichostatin 
A was the first natural product discovered to inhibit HDACs. After that, several molecules with 
similar structure started to be produced and tested as HDACi, such as SAHA or Belinostat.  
 
I.4.1 HDACi - multitargeted compounds 
 
HDACi have been studied as potential drugs for different final goals. The action of these 
inhibitors leads to a more open chromatin conformation and DNA becomes more accessible to 
several processes. One of those processes can be transcription, so HDACi have been correlated 
with higher transcription activity. Therefore, these compounds and analogues have been studied 
as potential additives capable of enhancing the expression of recombinant proteins in mammalian 
cell cultures (SME, from Small Molecule Enhancers)14. Recently, SME are being studied also in 
plant cell cultures within the same purpose.  
In the last decade, neurodegenerative diseases have also been proposed as targets for 
HDACi therapy. Brain disorders are often associated with imbalances in protein acetylation levels 
and transcriptional dysfunctions15. Treatment with various HDACi can potentially lead to the 
correction of these variations. In several animal models of neurodegenerative diseases (such as 
Parkinson´s disease and Alzheimer´s disease among others), treatments with HDACi revealed 
effectiveness against neuronal cell death and improved neurological outcome16,17.  
Cancer disease is another target of this type of compounds. HDACi have been studied 
as potential antitumor agents and there are now several approved as anti-cancer agents. Not only 
these compounds can act as radio-sensitizers in the treatment of cancer but also they show 
several effects against cancerous cells with an apparent selectivity, such as growth arrest, 
induction of apoptosis and cell cycle arrest.  (See sections I.4.2 and I.4.3).  
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I.4.2 HDACi as anticancer agents  
 
As mentioned before, the first evidences that epigenetics alterations, and especially 
histone acetylation could be involved in cancer came from studies showing different acetylation 
levels in cancerous and non-cancerous cells. Fraga et al showed global loss of monoacetylation 
and trimethylation of lysine residues in histone H4 in cancer cells5. In related studies, authors 
analyzed the expression of class I HDAC enzymes (HDAC1, 2, 3, and 8) in several cell lines and 
cancer tissues.  Stomach, oesophagus, colon, prostate, breast, ovary, lung, pancreas and thyroid 
cancers were analysed and the results showed that over 75% of human cancer tissues and their 
corresponding non-cancerous epithelium showed high expression of these class I HDACs. Also, 
5-40% of cancer tissues overexpressed class I HDACs, compared with corresponding normal 
epithelium18.  
Due to these and similar findings, inhibitors of HDAC enzymes emerged as a new class 
of targeted therapeutics for a variety of human cancers. Currently, there are several clinical trials 
of this type of drugs alone or in combination with drugs already used in cancer therapy. To date, 
four HDAC inhibitors were approved by the U.S Food and Drug Administration (FDA) for 
lymphoma and myeloma: Belinostat, Romidepsin, Panobinostat and SAHA (Table I.2).  
Belinostat (BELEODAQ, Spectrum Pharmaceuticals, Inc.) was approved by the FDA in 
July, 2014, for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma 
(PTCL)19. 
Romidepsin (ISTODAX, Gloucester Pharmaceuticals Inc.) was approved by the FDA in 
November, 2009, for the treatment of cutaneous T-cell lymphoma (CTCL) in patients that have 
received at least one prior systemic therapy19. 
Panobinostat (FARYDAK capsules, Novartis Pharmaceuticals) was approved by the FDA 
in February, 2015, in combination with bortezomib and dexamethasone for the treatment of 
patients with multiple myeloma20.                         
SAHA or Vorinostat (Zolinza, Merck & Co., Inc.) acts as a strong chelator of Zinc ions and 
is an effective HDAC inhibitor. SAHA was approved by the FDA for the treatment of cutaneous T-
cell lymphoma (CTCL) in October of 2006.21,22 SAHA is capable of inhibiting all HDAC in classes 
I and II that are metal dependent (in nanomolar range)23 so it is considered a pan-inhibitor of 
HDAC. However, like other HDACi, is not able of inhibiting class III HDAC.  
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Structurally, hydroxamic acids HDACi, such as SAHA, include three important domains: 
a capping group, a metal binding moiety and a linker. (Figure I.3)   
 
Figure I.3 - Structures of SAHA and Belinostat with their three important domains: capping group, linker and 
metal binding moiety. 
 
The capping group is important in the interaction with the amino acid residues near the 
entrance of the active site. The metal binding moiety is crucial for the interaction with the zinc 
atom present in the catalytic pocket of HDAC enzyme (Figure I.4). The linker connects the two 
groups10. In case of SAHA, the linker is only a carbon chain with 8 carbons without double bonds, 
but in Belinostat the linker is much shorter with a double bond.  Optimization of these key motifs 
is crucial for the discovery of a molecule better fitted to the catalytic pocket of the enzyme and 
consequently with higher potency, as HDAC inhibitor. 
 
 
 
 
 
 
 
 
 
 
Figure I.4 – Representation of the catalytic pocket 
in the crystal structure of HDAC protein with SAHA. 
In the catalytic pocket of HDAC enzyme is a Zinc 
molecule (in pink) where the hydroxamic part of 
SAHA binds. Adapted from Marks, P. A. et al 45. 
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I.4.3 HDACi Action Mechanism 
 
As previous mentioned in section I.1, cancer has been correlated in recent years with 
extensive reprogramming of epigenetic machinery components including DNA methylation and 
histone modifications. Treatment with HDACi can potentially lead to the correction of the 
epigenetic reprogramming found in cancer. HDACi have an important role in histone regulation, 
preventing the removal of acetyl groups from lysines by HDAC (see section I.2). Due to their effect 
in histone regulation, HDACi are responsible for an overall increase in acetylated histones causing 
altered gene transcription. HDACi can also act in other substrates leading to an increased 
acetylation level and altered gene transcription of non-histone proteins that are important 
regulators in several processes, resulting in numerous side effects that can also contribute to their 
anti-cancer action. Several studies have shown that HDACi can inhibit proliferation, stimulate 
apoptosis24, and induce cell cycle arrest25 in malignant cells10.  (Figure I.5) 
 
Figure I.5 - Biological effects of HDACi in malignant cells. Adapted from K.Ververis et al10. 
 
Moreover, the SAHA compound produces several effects in cancerous cells such as 
alteration in gene transcription, an increase of acetylated proteins, growth arrest in vitro and in 
vivo26, induction of apoptosis24 and cell cycle arrest25 with little toxicity to normal cells27. The 
mechanisms behind these anticancer effects are not fully understood but several efforts have 
been made to correlate the increase of acetylation in histone and non-histone proteins with the 
effects in malignant cells.  
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Some mechanisms normally dysregulated in cancer are apoptosis/cell death and cell 
cycle progression, enabling cancer cells to growth in an abnormal and very rapid manner and 
enabling them to overcome checkpoints that usually lead to cell death. Therefore, these type of 
dysregulations are hallmarks for ongoing tumor progression and good targets for anticancer 
drugs. 
Apoptosis is the process of programmed cell death and is mediated by intrinsic 
(mitochondrial) and extrinsic (death receptor) pathways. HDAC inhibitors induce apoptosis via 
both pathways by up-regulating pro-apoptotic and down-regulating anti-apoptotic proteins28,29. 
The p53 tumor suppressor gene encodes for a transcriptional factor whose activity is modulated 
by post-translational modifications including acetylation and protein stability. Studies showed that 
through acetylation of p53, HDACi were able to up-regulate pro-apoptotic proteins such as Bim, 
Bak, and Bax, which function as sensors of cellular stress and initiate the intrinsic pathway29. At 
a molecular level, apoptosis is caused by the activation of caspases29.  
Several HDAC inhibitors induce cell cycle arrest at G1 via induction of the cyclin-
dependent kinase inhibitor p21WAF/CIP1. HDAC inhibitors also induce G2/M arrest in normal and 
transformed cells, but the latter lack a functional G2 checkpoint and frequently undergo 
apoptosis28. 
As mentioned in section I.2, a higher acetylation of lysine residues of histones is 
correlated with a more open chromatin conformation. Therefore, DNA can be more accessible for 
DNA damage agents and reactive oxygen species (ROS) increasing the potential of causing DNA 
damage. Valproic acid has been reported to enhance the radiosensitivity of human tumour cells 
in vivo and in vitro. In mice, irradiation of brain tumour cells after treatment with valproic acid 
resulted in radiation-induced tumour growth delay30. Related studies with other HDACi showed 
similar results. Therefore, these compounds can act as radio-sensitizers, being helpful in 
combined therapies with radiotherapy for cancer treatment.  
One additional characteristic that makes HDACi appealing as anticancer agents is the 
fact that these inhibitors are normally correlated with a normal cell resistance phenomenon. They 
have antitumor action in cancerous cells at concentrations at which normal cells show little 
toxicity. Normal cells are up to tenfold more resistant to SAHA-induced cell death than cancer 
cells 27. The mechanism that leads to this selectivity of HDACi is not well understood and several 
studies tried to answer this question. One study suggests that thioredoxin, a small redox protein, 
has a key role in the response of normal and cancer cells to HDACi 27. They show that higher 
levels of thioredoxin in normal cells could explain, in part, the relative resistance of normal cells 
to these compounds effects. Low levels of thioredoxin in transformed cells increased their 
sensitivity to HDACi-induced cell death27.  
Another study claims that HDACi are able to induce DNA damage in both cancerous and 
non-cancerous cells but only normal cells can repair this damage 31. The authors demonstrated 
that SAHA is capable of inducing DNA double-strand breaks (DSB) in both normal (HFS-human 
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dermal fibroblasts) and cancer cells (LNCaP, A549). Using a marker of DNA DSB during 
continued culture with SAHA, the authors saw an increase in levels of that marker with time in 
cancer cells but a decrease in normal cells. Also, they found that SAHA was able to suppress 
DNA DSB repair proteins in cancer but not in normal cells31. 
 
I.4.4 HDACi Synthesis  
 
Based on previously published synthesis for HDAC inhibitors and derivatives, the 
synthesis of hydroxamic or carboxylic derivatives can be achieved in two steps 32–34 (See scheme 
in figure I.6).  
 
 
        
   
Figure I.6 - General scheme of HDAC inhibitors synthesis. 
 
The first step consists on the formation of an amide under an inert atmosphere (argon), 
using an aniline derivative and a carboxylic acid with a coupling agent such as 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) in dry dimethylformamide (DMF) . The obtained ester 
is then converted into its corresponding hydroxamic derivative by using hydroxylamine 
hydrochloride (NH2OH.HCl) in dry methanol (MeOH) for 1-2h.  The ester obtained in step 1 can 
also be transformed to its carboxylic derivate using sodium hydroxide (NaOH). The ester is 
dissolved in tetrahydrofuran (THF), NaOH added to the mixture and the reaction is stirred for 1-
2h. (See scheme in figure 6).    
Other reagents can be used as coupling agents such as N,N'-dicyclohexylcarbodiimide 
(DCC) and N,N'-Diisopropylcarbodiimide (DIC). 
1st STEP-
AMIDE 
FORMATION 
CARBOXYLIC 
ACID 
HYDROXAMIC 
ACID 
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As mentioned before (See section I.4.2), HDACi such as SAHA and Belinostat structurally 
contain three important domains: a capping group, a metal binding moiety and a linker. Several 
analogues were synthesized where these key aspects were altered in order to assess which 
structures are more important to the effectiveness of these compounds.  
Several analogues with different structures can be obtained changing the starting 
material and the aniline derivative used in the first step of synthesis. (See scheme in figure I.6). 
Different starting materials with different carbon lengths lead to analogues with different linkers. 
In this work, mono-ethyl fumarate, adipic acid monomethyl ester, suberic acid monomethyl ester 
and azelaic acid monomethyl ester were used as starting compounds. Also, different aniline 
derivatives used in the initial step (See scheme in figure I.6) will enable the synthesis of analogues 
containing different atoms in the benzenic ring, modifying the capping group.  
Furthermore, a metal chelator moiety is crucial in the HDACi structure. Not only the 
hydroxamic acid moiety but also the carboxylic moiety are good chelators of metal, even though 
the carboxylic acid is less efficient in this role. Therefore, carboxylic acid analogues can also have 
activity as inhibitors of HDAC and were also synthesized and tested in cancer cell lines.  
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I.5 Thesis aim  
 
The final goal of this work was to synthesize new HDAC inhibitors with anticancer effects. 
The first objective was to synthesize several compounds using the structures of SAHA and 
Belinostat as a starting point/model and evaluate them as anticancer agents in cancer cell lines. 
Within this purpose, the synthesized compounds were altered in key aspects of HDACi structure. 
All three important domains were changed: the capping group was altered with the addition of 
different atoms to the benzenic ring, the carbon length of linker was modified in different extents 
and both hydroxamic acid and carboxylic acid forms were synthesized. (Figure I.7).  
 
    
 
 
 
 
 
Figure I.7 - General structure of HDACi. 
 
These compounds were evaluated in cancer cell lines in parallel with SAHA as reference 
compound. The effect of the synthesized compounds on cell viability of a breast cancer cell line 
(MCF-7) and a lung cancer cell line (H460) was assessed in the presence and absence of the 
drugs to analyze which functional groups lead to a higher effect in cancer cells. 
The second objective was to refine the compound structures taking to account the results 
obtained in the first round of drug testing by synthesizing new molecules combining the best 
groups in the same molecule, when possible.   
The third objective was to evaluate these compounds in the same cancer cell lines and 
address the mechanisms of cell death of the compounds with higher impact on cancer cell 
viability. 
 
 
 
R1 – F, I, Br, CF3, OCH3 at 
different positions 
R2 – OH, NHOH  
n –  4,6, 7 
R2 – OH, NHOH 
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II. MATERIALS AND METHODS  
 
II.1 Synthesis of New HDACi 
 
II.1.1 General conditions 
 
All reactions were carried out under an inert atmosphere (argon), except when the 
solvents were not dried. The synthesized compounds were purified by recrystallization or silica 
flash-column chromatography. Reactions were followed by Analytical TLC (thin-layer 
chromatography). The characterization of compounds was done by 1H-NMR, 13C-NMR, 13C-APT, 
2D NMR techniques (COSY and HMQC), IR spectroscopy and melting point measurement. NMR 
peak assignments are supported by 2D correlation NMR studies and the peaks assigned when 
possible.  
Analytical TLC was performed on aluminium-backed Merck 60 F254 silica gel plates. The 
spots corresponding to the products were identified by UV radiation (254 nm) and then immersed 
on a 5% phosphomolybdic acid solution in ethanol to be revealed. Compounds with the 
hydroxamic acid moiety were revealed using a solution containing 1-5% iron chloride (III) and 0.5 
M HCl. After immersion in this solution, hydroxamic acids appear red instantly.  
Silica flash-column chromatography in Silica gel Merck 60 was used, when applicable.  
1H-NMR spectra were recorded on a Bruker 400 spectrometer and obtained at 400 MHz 
in CDCl3 (deuterated chloroform) or DMSO-d6 (deuterated dimethyl sulfoxide). Chemical shifts 
are given in ppm, downfield from tetramethylsilane, for solutions in CDCl3. 1H-NMR spectra were 
analyzed using BRUKER TOPSIN 2.1. 
13C-NMR spectra were recorded on a Bruker 400 spectrometer at 100.61 MHz in CDCl3 
or DMSO-d6. 13C-NMR spectra were analyzed using Bruker Topsin 2.1 software. 
IR spectra were measured on a Nicolet 6700 ATR-FTIR spectrometer with a diamond 
crystal. IR spectra were analyzed using Omnic software.  
Melting Points were measured twice for each compound using a BUCHI 530 apparatus 
that contains a paraffin bath.  
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Solvent and Reagent Purification 
All the used solvents were previously distilled in the laboratory. 
Aniline – distilled under reduced pressure.  
Dry DMF: to previously distilled DMF, calcium hydride (drying agent) was added and the 
mixture was left overnight, followed by decantation from the drying agent and distillation under 
reduced pressure. 
Dry THF: to previously distilled THF, sodium wire and benzophenone were added, and 
the mixture was refluxed under argon for several hours until the solvent turned deep blue in colour. 
Then the mixture was kept at low reflux, being only distilled before its utilization. 
Dry Methanol: to 50-70 mL of previously distilled methanol, 5g of magnesium turnings 
and iodine (0.5 g) were added. The mixture was refluxed until all the magnesium had been 
consumed. More methanol (1L) was added and the reflux was maintained for 2h before distillation.  
 
II.1.2 General methods  
 
Experiment A - General methods for the 1st Step synthesis – Amide formation 
The experimental procedure to obtain the amides started by dissolving the starting 
material (mono-ethyl fumarate (Aldrich), adipic acid monomethyl ester (Aldrich), suberic acid 
monomethyl ester (Carbosynth) or azelaic acid monomethyl ester (Aldrich)) in dry DMF. The 
respective aniline was added (1.5 equivalents) and EDC (Fluka), a coupling agent was added 
(1.5 equivalents) stepwise. Reactions were maintained overnight under argon at room 
temperature. TLC (5:5 hexane: ethyl acetate) confirmed that the initial product was totally 
consumed. Reactions were stopped with the addition of water followed by organic phase 
extraction using ethyl acetate. Later, ethyl acetate and also DMF were evaporated, the last step 
using high vacuum. After the work-up procedure, purifications of the compounds were done by 
recrystallization using hexane and ethyl acetate or by silica flash column chromatography. 
 
Experiment B - General methods for carboxylic acid synthesis  
Compounds previously synthesized in the amide formation step were dissolved in THF 
and then NaOH 1M (1 equivalent) solution was added to the mixture. Reactions were stirred 
between 1h and 2h with strong agitation at room temperature. TLC (5:5 hexane: ethyl acetate) 
was performed to monitor the reactions. The reactions were stopped when the starting material 
was totally consumed with the addition of water followed by a washing step using ethyl ether. 
Subsequently, the aqueous phase was acidified using a solution of HCl 10% until it reached a pH 
17 
 
3-4. Precipitation of product occurred and was followed by organic phase extraction using ethyl 
acetate. Then, ethyl acetate was evaporated. After the work-up procedure, the purification of the 
compounds was done by recrystallization using hexane and ethyl acetate. 
 
Experiment C - General methods for hydroxamic acid synthesis  
Compounds previously synthesized in the amide formation step were dissolved in dry 
MeOH and then NH2OH.HCl (Merck) was added (0.8 equivalents) to the mixture. The reactions 
were then placed on an ice bath (0ºC) and NaOH 4M (8 equivalents) was also added to the flask. 
The reactions were maintained for 1-2h under argon at 0ºC. TLC (5:5 hexane:ethyl acetate) was 
performed to monitor the reactions and the reactions were stopped when the starting material 
was totally consumed, by adding water followed by a washing step using ethyl ether. Next, the 
aqueous phase was acidified using an aqueous solution of HCl 10% until pH 3-4. Precipitation of 
the product occurred and was followed by organic phase extraction using ethyl acetate. A washing 
step using sodium bicarbonate (NaHCO3) was then performed and ethyl acetate phase was 
evaporated. After the work-up procedure, purification of the compounds was done by 
recrystallization using hexane and ethyl acetate.  
 
II.1.3 Experimental Procedures 
 
Experiment 1: Synthesis of ethyl (2E)-3-(phenylcarbamoyl)prop-2-enoate (1a) 
 
The procedure in experiment A was applied to the starting material mono-ethyl fumarate (0.5 g, 
3.5 mmol). Previously distilled aniline (5.2 mmol) was used in this experiment. Purification of the 
reaction crude performed by recrystallization afforded compound 1a (0.555 g, 73%) as a white 
solid. This reaction was repeated and compound 1a was also obtained (0.463 g, 61%).  
1H-NMR (CDCl3): δ 7.86 (1H, broad s, NH), 7.61 (2H, d, J= 7.8 Hz, Ar), 7.35 (2H, t, J=8.0 Hz, Ar), 
7.18 – 7.14 (1H, m, Ar), 7.12 (1H, d. J= 15.2 Hz, CH=CH), 6.96 (1H, d, J=15.3 Hz, CH=CH) ,4.28 
(2H, q, J=7.3 Hz, OCH2CH3), 1.33 (3H, t. J= 7.2 Hz, OCH2CH3) 
13C-NMR (CDCl3): δ 165.7 (C=O), 161.5 (C=O), 137.3 (Ar, quaternary C), 136.8 (C=C), 131.4 
(C=C), 129.1 (Ar), 125.0 (Ar), 120.0 (Ar), 61.4 (CH2CH3), 14.1 (CH2CH3) 
Melting Point – 105 °C 
FT-IR (ATR): 3348 (N-H), 1703 (C=O), 1677 (C=O) (vmax/cm-1) 
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Experiment 2: Synthesis of (2E) -3-(phenylcarbamoyl) prop-2-enoic acid (1b) 
 
The procedure in experiment B was applied to compound 1a (0.3 g, 1.4 mmol). Purification of the 
reaction crude performed by recrystallization afforded compound 1b (69 mg, 26 %) as a white 
solid.  
1H-NMR (DMSO-d6): δ 12.90 (1H, broad s, OH), 10.49 (1H, s, NH), 7.68 (2H, d, J= 7.7 Hz, Ar), 
7.35 (2H, t, J= 7.8 Hz, Ar), 7.15 (1H, d, J=15.3 Hz, Ar), 7.10 (1H, d, J= 7.4 Hz, CH=CH), 6.66 (1H, 
d, J= 15.3 Hz, (CH=CH). 
13C-NMR (DMSO-d6): δ 166.8 (C=O), 162.1 (C=O), 139.0 (Ar, quaternary C), 137.6 (C=C), 131.3 
(C=C), 129.4 (Ar), 124.5 (Ar), 119.8 (Ar). 
Melting Point – 228 °C 
FT-IR (ATR): 3305 (O-H), 1659 (C=O), 1644 (C=O) (vmax/cm-1) 
 
Experiment 3: Synthesis of (2E)-N-hydroxy-N'-phenylbut-2-enediamide (1c) 
 
The procedure in experiment C was applied to compound 1a (0.5 g, 2.3 mmol). Purification of the 
reaction crude performed by recrystallization afforded compound 1c (203 mg, 43 %) as a white 
solid.  
1H-NMR (DMSO-d6): δ 11.12 (1H, broad s, OH), 10.41 (1H, s, NH), 9.20 (1H, broad s, NH-OH), 
7.67 (2H, d, J= 7.8 Hz, Ar), 7.34 (2H, t, J= 7.8 Hz, Ar), 7.10 (1H, s, Ar), 7.08 (1H, d, J= 15.2 Hz, 
CH=CH), 6.82 (1H, d, J= 15.2 Hz, CH=CH).  
13C-NMR (DMSO-d6): δ 166.7 (C=O), 161.6 (C=O), 139.2 (Ar, quaternary C), 131.6 (C=C), 134.5 
(C=C), 129.3 (Ar), 124.3 (Ar), 119.8 (Ar). 
Melting Point – 197 °C 
FT-IR (ATR): 3250 (O-H), 1687 (C=O), 1649 (C=O) (vmax/cm-1) 
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Experiment 4: Synthesis of ethyl (2E)-3-[(4-fluorophenyl)carbamoyl]prop-2-enoate (2a) 
 
The procedure in experiment A was applied to mono-ethyl fumarate (0.8 g, 5.55 mmol). 2-
Fluoroaniline (8.3 mmol) was used in this experiment. Purification of the reaction crude performed 
by recrystallization afforded compound 2a (0.974 g, 74 %) as a white solid.  
1H-NMR (CDCl3): δ 7.86 (1H, broad s, NH), 7.59 – 7.56 (2H, m, Ar), 7.09 (1H, d, J= 15.3 Hz, 
CH=CH), 7.07 – 7.02 (2H, m, Ar), 6.95 (1H, d, J= 15.24 Hz, CH=CH), 4.27 (2H, q, J=7.2 Hz, 
OCH2CH3), 1.33 (3H, t. J= 7.2 Hz, OCH2CH3) 
13C-NMR (CDCl3): δ 165.6 (C=O), 161.5 (C=O), 160.1 (quaternary C, F-C), 136.4 (C=C), 133.4 
(Ar, quaternary C), 131.5 (C=C), 121.9 (Ar), 121.8 (Ar), 115.9 (Ar), 115.7 (Ar), 61.5 (CH2CH3), 
14.1 (CH2CH3) 
Melting Point – 149 °C 
FT-IR (ATR): 3302 (N-H), 1716 (C=O), 1670 (C=O) (vmax/cm-1) 
 
Experiment 5: Synthesis of (2E)-2-[(4-fluorophenyl)carbamoyl]prop-2-enoic acid (2b) 
 
The procedure in experiment B was applied to compound 2a (0.3 g, 1.3 mmol). Purification of the 
reaction crude performed by recrystallization afforded compound 2b (70 mg, 27 %) as a white 
solid.  
1H-NMR (DMSO-d6): δ 13.01 (1H, broad s, OH), 10.55 (1H, broad s, NH), 7.72 – 7.68 (2H, m, Ar), 
7.19 (2H, t, J= 8.8 Hz, Ar), 7.10 (1H, d, J= 15.4 Hz, CH=CH), 6.66 (1H, d, J= 15.4 Hz, CH=CH) 
13C-NMR (DMSO-d6): δ 166.7 (C=O), 162.0 (C=O), 160.1 (quaternary C, F-C), 137.3 (C=C), 135.4 
(Ar, quaternary C), 131.4 (C=C), 121.7 (Ar), 121.6 (Ar), 116.1 (Ar), 115.9 (Ar) 
Melting Point – 235 °C 
FT-IR (ATR): 3306 (O-H), 1658 (C=O), 1643 (C=O) (vmax/cm-1)  
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Experiment 6: Synthesis of (2E)-N'-(4-fluorophenyl)-N-hydroxybut-2-enediamide (2c) 
 
The procedure in experiment C was applied to compound 2a (0.4 g, 1.7 mmol). Purification of the 
reaction crude performed by recrystallization afforded compound 2c (147 mg, 39 %) as a white 
solid.  
1H-NMR (DMSO-d6): δ 11.10 (1H, broad s, OH), 10.49 (1H, s, NH), 9.32 (1H, broad s, NH-OH), 
7.71 – 7.66 (2H, m, Ar), 7.21 – 7.15 (2H, m, Ar), 7.06 (1H, d, J= 15.1 Hz, CH=CH), 6.82 (1H, d, 
J= 15.1 Hz, CH=CH) 
13C-NMR (DMSO-d6): δ 162.5 (C=O), 159.9 (C=O), 157.6 (quaternary C, F-C), 135.6 (Ar, 
quaternary C), 131.6 (C=C), 121.6 (Ar), 121.5 (Ar), 116.0 (Ar), 115.8 (Ar) 
Melting Point – 216 °C 
FT-IR (ATR): 3257 (O-H), 1687 (C=O), 1647 (C=O) (vmax/cm-1) 
 
Experiment 7: Synthesis of ethyl (2E)-3-[(2-bromophenyl)carbamoyl]prop-2-enoate (3a) 
 
The procedure in experiment A was applied to mono-ethyl fumarate (0.8 g, 5.55 mmol). 2-
Bromoaniline (8.3 mmol) was used in this experiment. Purification of the reaction crude performed 
by recrystallization afforded compound 3a (0.671 g, 41 %) as a brown solid.  
1H-NMR (CDCl3): δ 8.45 (1H, d, J= 8.1 Hz, Ar), 7.89 (1H, broad s, NH), 7.57 (1H, d, J=8.0 HZ, 
Ar), 7.35 (1H, t, J= 8.0 Hz, Ar), 7.09 (1H, d, J=15.3 Hz, CH=CH), 7.03 (1H, t, J= 8.0 Hz, Ar), 6.95 
(1H, d, J= 15.3 Hz, CH=CH), 4.29 (2H, q, J=7.2, OCH2CH3), 1.35 (3H, t. J= 7.12 Hz, OCH2CH3) 
13C-NMR (CDCl3): δ 166.7 (C=O), 161.5 (C=O), 136.1 (Ar, quaternary C), 135.7 (C=C), 131.8 
(Ar), 127.9 (Ar), 127.5 (C=C), 125.5 (Ar), 117.5 (quaternary C, Br-C), 61.4 (CH2CH3), 14.4 
(CH2CH3) 
Melting Point – 115 °C 
FT-IR (ATR): 3282 (N-H), 1712 (C=O), 1688 (C=O) (vmax/cm-1) 
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Experiment 8: Synthesis of (2E)-3-[(2-bromophenyl)carbamoyl]prop-2-enoic acid (3b) 
 
The procedure in experiment B was applied to compound 3a (0.3 g, 1 mmol). Purification of the 
reaction crude performed by recrystallization afforded compound 3b (133 mg, 49 %) as a brown 
solid.  
1H-NMR (DMSO-d6): δ 13.02 (1H, broad s, OH), 10.08 (1H, s, NH), 7.70 - 7.65 (2H, m, Ar), 7.41 
(1H, t, J= 7.8 Hz), 7.29 (1H. d, J= 15.4 Hz, CH=CH), 7.19 (1H, t, J= 7.9 Hz), 6.67 (1H, d, J= 15.4 
Hz, CH=CH) 
13C-NMR (DMSO-d6): δ 166.7 (C=O), 162.6 (C=O), 136.9 (C=C), 136.1 (Ar, quaternary C), 133.3 
(Ar), 131.9 (C=C), 128.5 (Ar), 128.1 (Ar), 127.8 (Ar), 118.5 (quaternary C, Br-C) 
Melting Point – 213 °C 
FT-IR (ATR): 3271 (O-H), 1696 (C=O), 1662 (C=O) (vmax/cm-1) 
 
Experiment 9: Synthesis of (2E)-N'-(2-bromophenyl)-N-hydroxybut-2-enediamide (3c) 
 
The procedure in experiment C was applied to compound 3a (0.3 g, 1 mmol). Purification of the 
reaction crude performed by recrystallization afforded compound 3c (146 mg, 51 %) as a white 
solid.  
1H-NMR (DMSO-d6): δ 11.11 (1H, s, OH), 10.01 (1H, s, NH), 9.32 (1H, broad s, NH-OH), 7.70 – 
7.65 (2H, m, Ar), 7.41 (1H, t, J= 7.4 Hz, Ar), 7.24 (1H, J= 15.2 Hz, CH=CH), 7.18 (2H, t, J= 7.4 
Hz, Ar), 6.84 (1H, d, J= 15.2 Hz, CH=CH) 
13C-NMR (DMSO-d6): δ 166.7 (C=O), 161.6 (C=O), 136.2 (Ar, quaternary C), 133.2 (C=C), 132.2 
(Ar), 128.5 (C=C), 128.0 (Ar), 127.8 (Ar), 117.5 (quaternary C, Br-C) 
Melting Point – 207 °C 
FT-IR (ATR): 3255 (O-H), 1672 (C=O), 1623 (C=O) (vmax/cm-1) 
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Experiment 10: Synthesis of ethyl (2E)-3-[(4-bromophenyl)carbamoyl]prop-2-enoate (4a) 
 
The procedure in experiment A was applied to mono-ethyl fumarate (0.8 g, 5.55 mmol). 4-
Bromoaniline (8.4 mmol) was used in this experiment. Purification of the reaction crude performed 
by recrystallization afforded compound 4a (1.484 g, 90 %) as a white solid.  
1H-NMR (CDCl3): δ 7.82 (1H, broad s, NH), 7.52 (2H, d, J=8.8 Hz, Ar), 7.46 (2H, d, J= 8.8 Hz, 
Ar), 7.07 (1H, d, J=15.3 Hz, CH=CH), 6.95 (1H, d, J= 15.3 Hz, CH=CH), 4.28 (2H, q, J=7.2 Hz, 
OCH2CH3), 1.33 (3H, t. J= 7.2 Hz, OCH2CH3) 
13C-NMR (CDCl3): δ 165.5 (C=O), 161.5 (C=O), 136.5 (Ar, quaternary C), 136.2 (C=C), 132.1 
(Ar), 131.8 (C=C), 121.5 (Ar), 117.8 (quaternary C, Br-C), 61.5 (CH2CH3), 14.1 (CH2CH3) 
Melting Point – 159 °C 
FT-IR (ATR): 3295 (N-H), 1712 (C=O), 1669 (C=O) (vmax/cm-1) 
 
Experiment 11: Synthesis of (2E)-3-[(4-bromophenyl)carbamoyl]prop-2-enoic acid (4b) 
 
The procedure in experiment B was applied to compound 4a (0.3 g, 1 mmol). Purification of the 
reaction crude performed by recrystallization afforded compound 4b (202 mg, 74 %) as a white 
solid.  
1H-NMR (DMSO-d6): δ 13.03 (1H, broad s, OH), 10.62 (1H, s, NH), 7.64 (2H, d, J= 8.9 Hz, Ar), 
7.53 (2H, d, J=8.8 Hz, Ar), 7.11 (1H, d, J=15.4 Hz, CH=CH), 6.66 (1H, d, J= 15.4 Hz, CH=CH)  
13C-NMR (DMSO-d6): δ 166.7 (C=O), 162.2 (C=O), 138.4 (Ar, quaternary C), 137.3 (C=C), 132.2 
(Ar), 131.5 (C=C), 121.8 (Ar), 116.2 (quaternary C, Br-C) 
Melting Point – >250 °C 
FT-IR (ATR): 3296 (O-H), 1656 (C=O), 1647 (C=O) (vmax/cm-
1) 
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Experiment 12: Synthesis of (2E)-N'-(4-bromophenyl)-N-hydroxybut-2-enediamide (4c) 
 
The procedure in experiment C was applied to compound 4a (0.4 g, 1.3 mmol). Purification of the 
reaction crude performed by recrystallization afforded compound 4c (110 mg, 29 %) as a 
yellowish solid.  
1H-NMR (DMSO-d6): δ 11.15 (1H, broad s, OH), 10.59 (1H, s, NH), 9.36 (1H, broad s, NH-OH), 
7.65 (2H, d, J=8.8 Hz, Ar), 7.53 (2H, d, J= 8.8 Hz, Ar), 7.07 (1H, d, J=15.3 Hz, CH=CH), 6.83 (1H, 
d, J= 15.3 Hz, CH=CH) 
13C-NMR (DMSO-d6): δ 164.5 (C=O), 162.8 (C=O), 138.6 (Ar, quaternary C), 132.2 (Ar), 131.9 
(C=C), 121.7 (Ar), 115.9 (quaternary C, Br-C).  
Melting Point – 247 °C  
FT-IR (ATR): 3207 (O-H), 1648 (C=O), 1621 (C=O) (vmax/cm-1) 
 
Experiment 13: Synthesis of ethyl (2E)-3-[(2-fluorophenyl)carbamoyl]prop-2-enoate (5a) 
 
The procedure in experiment A was applied to mono-ethyl fumarate (0.8 g, 5.55 mmol). 2-
Fluoroaniline (8.4 mmol) was used in this experiment. Purification of the reaction crude performed 
by recrystallization afforded compound 5a (0.671 g, 52 %) as a white solid.  
1H-NMR (CDCl3): δ 8.41 (1H, t, J=8.1 Hz, Ar), 7.66 (1H, broad s, NH), 7.19 – 7.12 (3H, m, Ar), 
7.07 (1H, d, J=15.3 Hz, CH=CH), 6.95 (1H, d, J= 15.3 Hz, CH=CH), 4.29 (2H, q, J=7.2 Hz, 
OCH2CH3), 1.34 (3H, t, J= 7.2 Hz, OCH2CH3) 
13C-NMR (CDCl3): δ 165.2 (C=O), 161.4 (C=O), 158.3 (F-C, quaternary C), 144.1 (Ar, quaternary 
C), 135.8(C=C), 132.1 (C=C), 125.2 (Ar), 124.7 (Ar), 121.8 (Ar), 114.9 (Ar), 61.4 (CH2CH3), 14.2 
(CH2CH3) 
Melting Point – 96 °C 
FT-IR (ATR): 3355 (N-H), 1710 (C=O), 1678 (C=O) (vmax/cm-1) 
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Experiment 14: Synthesis of (2E)-3-[(2-fluorophenyl)carbamoyl]prop-2-enoic acid (5b)  
 
The procedure in experiment B was applied to compound 5a (0.3 g, 1.3 mmol). Purification of the 
reaction crude performed by recrystallization afforded compound 5b (195 mg, 74 %) as a white 
solid.  
1H-NMR (DMSO-d6): δ 13.01 (1H, s, OH), 10.32 (1H, s, NH), 8.03 – 7.99 (1H, m, Ar), 7.33 (2H. 
d, J= 15.4 Hz, CH=CH), 7.30 – 7.26 (1H, m, Ar), 7.23 – 7.18 (2H, m, Ar), 6.68 (1H, d, J= 15.4 Hz, 
CH=CH) 
13C-NMR (DMSO-d6): δ 166.7 (C=O), 162.6 (C=O), 155.3 (F-C, quaternary C), 152.8 (Ar, 
quaternary C), 136.9 (C=C), 131.8 (C=C), 126.4 (Ar), 124.9 (Ar), 124.5 (Ar), 115.9 (Ar) 
Melting Point – 215 °C 
FT-IR (ATR): 3290 (O-H), 1693 (C=O), 1665 (C=O) (vmax/cm-1) 
 
Experiment 15: Synthesis of (2E)-N'-(2-fluorophenyl)-N-hydroxybut-2-enediamide (5c) 
 
The procedure in experiment C was applied to compound 5a (0.282 g, 1.2 mmol). Purification of 
the reaction crude performed by recrystallization afforded compound 5c (98 mg, 37 %) as a white 
solid.  
1H-NMR (DMSO-d6): δ 11.10 (1H, broad s, OH), 10.23 (1H, s, NH), 9.33 (1H, broad s, NH-OH), 
8.01 – 7.96 (1H, m, Ar), 7.31 – 7.17 (4H, m, Ar and CH=CH), 6.84 (1H, d, J= 15.16 Hz, CH=CH).  
13C-NMR (DMSO-d6): δ 166.7 (C=O), 163.1 (C=O), 155.3 (F-C, quaternary C), 132.2 (C=C), 126.3 
(C=C), 126.2 (Ar, quaternary C), 124.9 (Ar), 124.6 (Ar), 116.1 (Ar), 115.9 (Ar) 
Melting Point – 212 °C 
FT-IR (ATR): 3067 (O-H), 1681 (C=O), 1614 (C=O) (vmax/cm-1) 
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Experiment 16: Synthesis of ethyl (2E)-3-[(2-chlorophenyl)carbamoyl]prop-2-enoate (6a) 
 
 
 
The procedure in experiment A was applied to mono-ethyl fumarate (0.8 g, 5.55 mmol). 2-
chloroaniline (8.3 mmol) was used in this experiment. Purification of the reaction crude performed 
by recrystallization afforded compound 6a (0.758 g, 54 %) as a white solid.  
1H-NMR (CDCl3): δ 8.52 (1H, t, J=8.1 Hz, Ar), 7.91 (1H, broad s, NH), 7.42 (1H, d, J= 8.1 Hz, Ar), 
7.31 (1H, t, J=8.0 Hz, Ar) 7.12 – 7.07 (2H, m. Ar and CH=CH), 6.95 (1H, d, J= 15.3 Hz, CH=CH), 
4.29 (2H, q, J=7.2 Hz, OCH2CH3), 1.35 (3H, t, J= 7.2 Hz, OCH2CH3) 
13C-NMR (CDCl3): δ 165.2 (C=O), 160.6 (C=O), 134.1 (Ar, quaternary C), 136.1(C=C), 132.1 
(C=C), 129.1 (Ar),128.2 (Cl-C, quaternary C), 127.9 (Ar), 125.4 (Ar), 121.8 (Ar), 121.6 (Ar), 61.4 
(CH2CH3), 14.2 (CH2CH3) 
Melting Point – 100 °C 
FT-IR (ATR): 3282 (N-H), 1712 (C=O), 1667 (C=O) (vmax/cm-1) 
 
Experiment 17: Synthesis of (2E)-3-[(2-chlorophenyl)carbamoyl]prop-2-enoic acid (6b) 
 
The procedure in experiment B was applied to compound 6a (0.3 g, 1.1 mmol). Purification of the 
reaction crude performed by recrystallization afforded compound 6b (233 mg, 88 %) as a white 
solid.  
1H-NMR (DMSO-d6): δ 12.96 (1H, broad s, OH), 10.13 (1H, s, NH), 7.79 (1H, d, J=7.9 Hz, Ar), 
7.53 (1H, d, J= 7.9 Hz, Ar), 7.39 – 7.32 (2H, m, Ar and CH=CH), 7.25 (1H, t, J=7.8 Hz, Ar), 6.68 
(1H, d, J= 15.4 Hz, CH=CH) 
13C-NMR (DMSO-d6): δ 166.8 (C=O), 162.6 (C=O), 137.0 (C=C), 134.7 (Ar, quaternary C), 131.8 
(C=C), 130.1 (Ar), 127.9 (Ar), 127.4 (Ar), 127.1 (quaternary C, Cl-C), 126.8 (Ar) 
Melting Point – 220 °C 
FT-IR (ATR): 3275 (O-H), 1694 (C=O), 1663 (C=O) (vmax/cm-1) 
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Experiment 18: Synthesis of (2E)-N'-(2-chlorophenyl)-N-hydroxybut-2-enediamide (6c) 
 
The procedure in experiment C was applied to compound 6a (0.3 g, 1.1 mmol). Purification of the 
reaction crude performed by recrystallization afforded compound 6c (70 mg, 25 %) as a white 
solid.  
1H-NMR (DMSO-d6): δ 11.13 (1H, broad s, OH), 10.06 (1H, s, NH), 9.35 (1H, broad s, NH-OH), 
7.77 (1H, d, J=7.9 Hz, Ar), 7.5 (1H, d, J= 8.0 Hz, Ar), 7.36 (1H, d, J=7.9 Hz, Ar), 7.28 – 7.21 (2H, 
m, Ar and CH=CH), 6.84 (1H, d, J=15.2 Hz, CH=CH) 
13C-NMR (DMSO-d6): δ 166.1 (C=O), 163.1 (C=O), 134.9 (Ar, quaternary C), 132.2 (C=C), 130.0 
(C=C), 127.9 (Ar), 127.3 (quaternary C, Cl-C), 127.3 (Ar), 126.9 (Ar) 
Melting Point – 202 °C 
FT-IR (ATR): 3255 (O-H), 1638 (C=O), 1618 (C=O) (vmax/cm-1) 
 
Experiment 19: Synthesis of ethyl (2E)-3-[(2-bromo-4-fluorophenyl)carbamoyl]prop-2-
enoate (7a) 
 
The procedure in experiment A was applied to mono-ethyl fumarate (0.8 g, 5.55 mmol). 2-Bromo-
4-fluoroaniline (8.3 mmol) was used in this experiment. Purification of the reaction crude 
performed by recrystallization afforded compound 7a (1g, 38 %) as a white solid.  
1H-NMR (CDCl3): δ 8.44 – 8.41 (1H, m, Ar), 7.77 (1H, broad s, NH), 7.35 – 7.32 (1H, m, Ar), 7.12–
7.05 (2H, m, Ar and CH=CH), 6.95 (1H, d, J= 15.3 Hz, CH=CH), 4.30 (2H, q, J=7.2 Hz, OCH2CH3), 
1.35 (3H, t, J= 7.2 Hz, OCH2CH3) 
13C-NMR (CDCl3): δ 165.2 (C=O), 160.2 (C=O), 151.4 (F-C, quaternary C), 135.9 (C=C), 132.2 
(C=C), 131.6 (Ar, quaternary C), 123.1 (Ar), 120.5 (Br-C, quaternary C), 119.5 (Ar), 115.4 (Ar), 
61.5 (CH2CH3), 14.2 (CH2CH3) 
Melting Point – 130 °C 
FT-IR (ATR): 3265 (N-H), 1714 (C=O), 1669 (C=O) (vmax/cm-1) 
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Experiment 20: Synthesis of (2E)-3-[(2-bromo-4-fluorophenyl)carbamoyl]prop-2-enoic 
acid (7b) 
 
The procedure in experiment B was applied to compound 7a (0.3 g, 0.95 mmol). Purification of 
the reaction crude performed by recrystallization afforded compound 7b (243 mg, 89%) as a white 
solid.  
1H-NMR (DMSO-d6): δ 13.05 (1H, broad s, OH), 10.13 (1H, s, NH), 7.70 – 7.63 (2H, m, Ar), 7.34 
– 7.28 (1H, m, Ar), 7.25 (1H, d, J=15.4 Hz, CH=CH), 6.68 (1H, d, J=15.3 Hz, CH=CH) 
13C-NMR (DMSO-d6): δ 166.7 (C=O), 162.8 (C=O), 161.2 (quaternary C, F-C), 136.8 (C=C), 132.8 
(Ar, quaternary C), 131.9 (C=C), 129.4 (Ar), 120.1 (Ar), 119.5 (quaternary C, Br-C), 115.5 (Ar) 
Melting Point – 230 °C 
FT-IR (ATR): 3258 (O-H), 1698 (C=O), 1660 (C=O) (vmax/cm-1) 
 
Experiment 21:  Synthesis of (2E)-N'-(2-bromo-4-fluorophenyl)-N-hydroxybut-2-
enediamide (7c) 
 
The procedure in experiment C was applied to compound 7a (0.3 g, 1.1 mmol). Purification of the 
reaction crude performed by recrystallization afforded compound 7c (79 mg, 27 %) as a white 
solid.  
1H-NMR (DMSO-d6): δ 11.10 (1H, broad s, OH), 10.05 (1H, s, NH), 9.33 (1H, broad s, NH-OH), 
7.69 – 7.62 (2H, m, Ar), 7.30 (1H, t, J= 8.2 Hz, Ar), 7.20 (1H, d, J= 15.2 Hz, CH=CH), 6.83 (1H, 
d, J= 15.2 Hz, CH=CH) 
13C-NMR (DMSO-d6): δ 166.7 (C=O), 161.6 (C=O), 160.7 (quaternary C, F-C), 134.5 (C=C), 131.6 
(Ar, quaternary C), 130.8 (C=C), 125.4 (Ar), 124.2 (quaternary C, Br-C), 120.9 (Ar), 114.7 (Ar) 
Melting Point – 203 °C 
FT-IR (ATR): 3259 (O-H), 1638 (C=O), 1614 (C=O) (vmax/cm-1) 
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Experiment 22: Synthesis of ethyl (2E)-3-{[4-(trifluoromethyl)phenyl]carbamoyl}prop-2-
enoate (8a) 
 
The procedure in experiment A was applied to mono-ethyl fumarate (0.8 g, 5.55 mmol. 4-
(Trifluoromethyl)aniline (8.3 mmol) was used in this experiment. Purification of the reaction crude 
performed by recrystallization afforded compound 8a (1.136 g, 71 %) as a white solid.  
1H-NMR (CDCl3): δ 8.00 (1H, broad s, NH), 7.75 (1H, d, J= 8.3 Hz, Ar), 7.61 (1H, d, J= 8.4 Hz, 
Ar), 7.11 (1H, d, J= 15.3 Hz, CH=CH), 6.98 (1H, d, J= 15.4 Hz, CH=CH), 4.29 (2H, q, J=7.2 Hz, 
OCH2CH3), 1.34 (3H, t, J= 7.1 Hz, OCH2CH3) 
13C-NMR (CDCl3): δ 166.7 (C=O), 162.5 (C=O), 140.9 (Ar, quaternary C), 135.7 (C=C), 133.1 
(C=C), 132.1 (C-CF3, quaternary C), 125.3 (Ar), 124.1 (C-CF3, quaternary C), 121.9 (Ar), 61.4 
(CH2CH3), 14.2 (CH2CH3) 
Melting Point – 180 °C 
FT-IR (ATR): 3350 (N-H), 1702 (C=O), 1682 (C=O) (vmax/cm-1) 
 
Experiment 23: Synthesis of (2E)-3-{[4-(trifluoromethyl)phenyl]carbamoyl}prop-2-enoic 
acid (8b) 
 
The procedure in experiment B was applied to compound 8a (0.3 g, 1.2 mmol). Purification of the 
reaction crude performed by recrystallization afforded compound 8b (211 mg, 70%) as a white 
solid.  
1H-NMR (DMSO-d6): δ 13.08 (1H, broad s, OH), 10.84 (1H, s, NH), 7.88 (2H, d, J=8.4 Hz, Ar), 
7.73 (2H, d, J= 8.4 Hz, Ar), 7.15 (1H, d, J= 15.4 Hz, CH=CH), 6.70 (1H, d, J= 15.4 Hz, CH=CH) 
13C-NMR (DMSO-d6): δ 166.6 (C=O), 162.6 (C=O), 142.7 (Ar, quaternary C), 137.0 (C=C), 131.9 
(C=C), 126.6 (Ar), 126.1 (C-CF3, quaternary C), 124.4 (C-CF3, quaternary C), 119.9 (Ar) 
Melting Point – >250 °C 
FT-IR (ATR): 3304 (O-H), 1695 (C=O), 1662 (C=O) (vmax/cm-1) 
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Experiment 24: Synthesis of (2E)-N-hydroxy-N'-[4-trifluoromethyl)phenyl]but-2-
enediamide (8c) 
 
The procedure in experiment C was applied to compound 8a (0.35 g, 1.2 mmol). Purification of 
the reaction crude performed by recrystallization afforded compound 8c (326 mg, 97 %) as a 
yellow solid.  
1H-NMR (DMSO-d6): δ 11.10 (1H, broad s, OH), 10.59 (1H, s, NH), 9.50 (1H, broad s, NH-OH), 
7.89 (2H, d, J= 8.3 Hz, Ar), 7.66 (2H, d, J= 8.4 Hz, Ar), 6.81–6.73 (2H, m, CH=CH and CH=CH) 
13C-NMR (DMSO-d6): δ 165.1 (C=O), 163.6 (C=O), 143.8 (Ar, quaternary C), 138.9 (C=C), 132.3 
(C=C), 126.5 (Ar), 126.4 (C-CF3, quaternary C), 123.6 (C-CF3, quaternary C), 119.4 (Ar) 
Melting Point – 213 °C 
FT-IR (ATR): 3301 (O-H), 1636 (C=O), 1603 (C=O) (vmax/cm-1) 
 
Experiment 25: Synthesis of ethyl (2E)-3-[(3-methoxyphenyl)carbamoyl]prop-2-enoate (9a) 
 
The procedure in experiment A was applied to mono-ethyl fumarate (0.8 g, 5.55 mmol). 3-
Methoxyaniline (8.3 mmol) was used in this experiment. Purification of the reaction crude 
performed by recrystallization using afforded compound 9a (0.971 g, 70.4 %) as a white solid.  
1H-NMR (CDCl3): δ 7.72 (1H, broad s, NH), 7.24 (2H, t, J= 8.2 Hz, Ar), 7.11-7.05 (2H, m, Ar and 
CH=CH), 6.95 (1H, d, J= 15.2 Hz, CH=CH), 6.73-6.70 (1H, m, Ar), 4.28 (2H, q, J=7.2 Hz, 
OCH2CH3), 1.34 (3H, t, J= 7.1 Hz, OCH2CH3) 
13C-NMR (CDCl3): δ 165.6 (C=O), 161.5 (C=O), 160.2 (C-OCH3, quaternary), 136.7 (C=C), 132.1 
(Ar, quaternary C), 131.5 (C=C), 129.8 (Ar), 112.1 (Ar), 110.9 (Ar), 105.8 (Ar), 61.4 (CH2CH3), 
55.3 (C-OCH3, quaternary C), 14.1 (CH2CH3) 
Melting Point – 110 °C 
FT-IR (ATR): 3354 (N-H), 1704 (C=O), 1681 (C=O) (vmax/cm-1) 
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Experiment 26: Synthesis of (2E)-3-[(3-methoxyphenyl)carbamoyl]prop-2-enoic acid (9b) 
 
The procedure in experiment B was applied to compound 9a (0.3 g, 1.2 mmol). Purification of the 
reaction crude performed by recrystallization afforded compound 9b (237 mg, 89%) as a white 
solid.  
1H-NMR (DMSO-d6): δ 13.02 (1H, broad s, OH), 10.49 (1H, s, NH), 7.25 (1H, t, J= 8.0 Hz, Ar), 
7.19 (1H, d, J= 8.1 Hz, Ar), 7.13 (1H, d, J=15.4 Hz, CH=CH), 6.71 – 6.68 (1H, m, Ar), 6.66 (1H, 
d, J=15.4 Hz, CH=CH) 
13C-NMR (DMSO-d6): δ 166.7 (C=O), 162.1 (C=O), 159.9 (C-OCH3, quaternary), 140.2 (Ar, 
quaternary C), 137.6 (C=C), 131.2 (C=C), 130.1 (Ar), 112.2 (Ar), 109.9 (Ar), 105.7 (Ar), 55.5 (C-
OCH3, quaternary C) 
Melting Point – 195 °C 
FT-IR (ATR): 3292 (O-H), 1697 (C=O), 1658 (C=O) (vmax/cm-1) 
 
Experiment 27: Synthesis of (2E)-N-hydroxy-N'-(3-methoxyphenyl)but-2-enediamide (9c) 
 
The procedure in experiment C was applied to compound 9a (0.35 g, 1.4 mmol). Purification of 
the reaction crude performed by recrystallization afforded compound 9c (30 mg, 15 %) as a yellow 
solid. 
1H-NMR (DMSO-d6): δ 11.12 (1H, broad s, OH), 10.42 (1H, s, NH), 9.34 (1H, broad s, NH-OH), 
7.27 – 7.18 (2H, m, Ar), 7.08 (1H, d, J= 15.1 Hz, CH=CH), 6.81 (1H, d, J= 15.1 Hz, CH=CH), 6.70 
– 6.66 (1H, m, Ar) 
13C-NMR (DMSO-d6): δ 166.6 (C=O), 162.6 (C=O),159.9 (C-OCH3, quaternary), 140.4 (Ar, 
quaternary C), 132.9 (C=C), 131.7 (C=C), 130.1 (Ar), 112.1 (Ar), 109.7 (Ar), 105.7 (Ar), 55.5 (C-
OCH3, quaternary C) 
Melting Point – 212 °C 
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FT-IR (ATR): 3209 (O-H), 1649 (C=O), 1618 (C=O) (vmax/cm-1) 
 
Experiment 28: Synthesis of ethyl (2E)-3-[(2-iodophenyl)carbamoyl]prop-2-enoate (10a) 
 
The procedure in experiment A was applied to mono-ethyl fumarate (0.6 g, 4.2 mmol). 2-
iodoaniline (6.2 mmol) was used in this experiment. Purification of the reaction crude performed 
by recrystallization afforded compound 10a (0.696 g, 48 %) as a white solid.  
1H-NMR (CDCl3): δ 8.34 (1H, d, J= 7.9 Hz, Ar), 7.81 (1H, d, J= 7.9 Hz, Ar), 7.72 (1H, broad s, 
NH), 7.38 (1H, t, J= 8.1 Hz, Ar). 7.09 (1H, t, J= 15.2 Hz, CH=CH), 6.96 (1H, d, J= 15.2 Hz, 
CH=CH), 6.90 (1H, t, J= 7.9, Ar), 4.29 (2H, q, J=7.1 Hz, OCH2CH3), 1.35 (3H, t, J= 7.1 Hz, 
OCH2CH3) 
13C-NMR (CDCl3): δ 165.2 (C=O), 161.7 (C=O), 138.9 (C=C), 137.6 (Ar, quaternary C), 136.2 
(C=C), 132.0 (Ar), 129.4 (Ar), 126.7 (Ar), 122.0 (Ar), 95.2 (C-I, quaternary C), 61.5 (CH2CH3), 
14.2 (CH2CH3) 
Melting Point – 128 °C 
FT-IR (ATR): 3273 (N-H), 1709 (C=O), 1667 (C=O) (vmax/cm-1) 
 
Experiment 29: Synthesis of (2E)-3-[(2-iodophenyl)carbamoyl]prop-2-enoic acid (10b) 
 
The procedure in experiment B was applied to compound 10a (0.25 g, 0.7 mmol). Purification of 
the reaction crude performed by recrystallization afforded compound 10b (222 mg, 97 %) as a 
white solid.  
1H-NMR (DMSO-d6): δ 13.03 (1H, broad s, OH), 10.06 (1H, s, NH), 7.92 (1H, t, J= 7.9 Hz, Ar), 
7.49 – 7.40 (2H, m, Ar), 7.24 (1H, d, J=15.4 Hz, CH=CH), 7.04 (1H, t, J=7.9 Hz, Ar), 6.67 (1H, d, 
J=15.5 Hz, CH=CH) 
13C-NMR (DMSO-d6): δ 166.8 (C=O), 162.5 (C=O), 139.5 (C=C), 139.4 (Ar, quaternary C), 137.1 
(C=C), 131.7 (Ar),129.2 (Ar), 128.7 (Ar), 127.9 (Ar), 96.9 (C-I, quaternary C) 
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Melting Point – 235 °C 
FT-IR (ATR): 3262 (O-H), 1698 (C=O), 1662 (C=O) (vmax/cm-1) 
 
Experiment 30: Synthesis of (2E)-N-hydroxy-N'-(2-iodophenyl)but-2-enediamide (10c) 
 
The procedure in experiment C was applied to compound 10a (0.35 g, 1 mmol). Purification of 
the reaction crude performed by recrystallization afforded compound 10c (141 mg, 42 %) as a 
yellow solid.  
1H-NMR (DMSO-d6): δ 11.09 (1H, broad s, OH), 9.97 (1H, s, NH), 9.33 (1H, broad s, NH-OH), 
7.91 (1H, d, J=7.8 Hz, Ar), 7.48–7.39 (2H, m, Ar), 7.18 (1H, d, J= 15.1 Hz, CH=CH), 7.03 (1H, t, 
J= 7.9 Hz, Ar), 6.83 (1H, d, J= 15.1 Hz, CH=CH),  
13C-NMR (DMSO-d6): δ 166.7 (C=O), 161.6 (C=O), 139.6 (Ar, quaternary C), 139.5 (C=C), 132.1 
(C=C), 129.1 (Ar), 128.6 (Ar), 127.9 (Ar), 97.0 (C-I, quaternary C) 
Melting Point – 210 °C 
FT-IR (ATR): 3249 (O-H), 1637 (C=O), 1615 (C=O) (vmax/cm-1) 
 
Experiment 31: Synthesis of ethyl (2E)-3-[(4-iodophenyl)carbamoyl]prop-2-enoate (11a) 
 
The procedure in experiment A was applied to mono-ethyl fumarate (0.6 g, 4.2 mmol). 4-
iodoaniline (6.2 mmol) was used in this experiment. Purification of the reaction crude performed 
by recrystallization afforded compound 11a (1.128 g, 81 %) as a purple solid.  
1H-NMR (CDCl3): δ 7.77 (1H, broad s, NH), 7.65 (2H, d, J= 8.7 Hz, Ar), 7.39 (2H, d, J=8.7 Hz, 
Ar), 7.07 (1H, t, J= 15.4 Hz, CH=CH), 6.95 (1H, d, J= 15.4 Hz, CH=CH), 4.28 (2H, q, J=7.3 Hz, 
OCH2CH3), 1.34 (3H, t, J= 7.4 Hz, OCH2CH3) 
13C-NMR (CDCl3): δ 165.6 (C=O), 161.5 (C=O), 138.1 (C=C), 137.1 (Ar, quaternary C), 136.2 
(C=C), 131.9 (Ar), 121.8 (Ar), 88.6 (C-I, quaternary C), 61.5 (CH2CH3), 14.1 (CH2CH3) 
Melting Point – 157 °C 
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FT-IR (ATR): 3338 (N-H), 1704 (C=O), 1668 (C=O) (vmax/cm-1) 
 
Experiment 32: Synthesis of (2E)-3-[(4-iodophenyl)carbamoyl]prop-2-enoic acid (11b) 
 
The procedure in experiment B was applied to compound 11a (0.3 g, 0.9 mmol). Purification of 
the reaction crude performed by recrystallization afforded compound 11b (243 mg, 88 %) as a 
gray solid.  
1H-NMR (DMSO-d6): δ 13.03 (1H, broad s, OH), 10.60 (1H, s, NH), 7.69 (2H, d, J= 8.7 Hz, Ar), 
7.51 (2H, d, J=8.7 Hz, Ar), 7.12 (1H, d, J=15.5 Hz, CH=CH), 6.66 (1H, d, J=15.6 Hz, CH=CH) 
13C-NMR (DMSO-d6): δ 166.7 (C=O), 162.2 (C=O), 138.9 (Ar, quaternary C), 138.0 (Ar), 137.3 
(C=C), 131.5 (C=C), 121.1 (Ar), 88.3 (C-I, quaternary C) 
Melting Point – >250 °C 
FT-IR (ATR): 3291 (O-H), 1695 (C=O), 1655 (C=O) (vmax/cm-1) 
 
Experiment 33: Synthesis of (2E)-N-hydroxy-N'-(4-iodophenyl)but-2-enediamide (11c) 
 
The procedure in experiment C was applied to compound 11a (0.35 g, 1 mmol). Purification of 
the reaction crude performed by recrystallization afforded compound 11c (103 mg, 31 %) as a 
white solid.  
1H-NMR (DMSO-d6): δ 11.11 (1H, broad s, OH), 10.53 (1H, s, NH), 9.32 (1H, s, NH-OH), 7.68 
(2H, d, J=8.6 Hz, Ar), 7.51 (2H, t, J=8.5 Hz, Ar), 7.08 (1H, d, J= 15.2 Hz, CH=CH), 6.82 (1H, d, 
J= 15.2 Hz, CH=CH) 
13C-NMR (DMSO-d6): δ 166.7 (C=O), 161.6 (C=O), 138.5 (Ar, quaternary C), 137.8 (Ar), 137.3 
(C=C), 131.5 (C=C), 121.1 (Ar), 86.1 (C-I, quaternary C) 
Melting Point – 250 °C 
FT-IR (ATR): 3264 (O-H), 1671 (C=O), 1621 (C=O) (vmax/cm-1) 
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Experiment 34: Synthesis of 5‐(phenylcarbamoyl)pentanoate (12a) 
 
The procedure in experiment A was applied to adipic acid monomethyl ester (0.3 g,1.9 mmol). 
Previously distilled aniline (2.8 mmol) was used in this experiment. Purification of the reaction 
mixture by flash-column chromatography (7:3 hexane-ethyl acetate) afforded compound 12a  
(412 mg, 94 %) as a white solid.  
1H-NMR (CDCl3): δ 7.53 (2H, d, J=7.9 Hz, Ar), 7.36 (1H, s, NH), 7.32 (2H, t, J=7.8 Hz, Ar), 7.10 
(1H, t, J=7.3 Hz, Ar), 3.68 (3H, s, O-CH3), 2.39 – 2.37 (4H, m, CH2), 1.79 – 1.71 (4H, m, CH2) 
13C-NMR (CDCl3): δ 174.1 (C=O), 170.8 (C=O), 137.9 (Ar, quaternary C), 128.9 (Ar), 124.2 (Ar), 
119.8 (Ar), 51.6 (O-CH3), 37.2 (CH2), 33.6 (CH2), 24.9 (CH2), 24.2 (CH2) 
Melting Point – 50 °C 
FT-IR (ATR): 3348 (N-H), 1703 (C=O), 1677 (C=O) (vmax/cm-1) 
 
Experiment 35: Synthesis of N-hydroxy-N'-phenylhexanediamide (12c) 
 
The procedure in experiment C was applied to compound 12a (0.2 g, 0.85 mmol). Purification of 
the reaction crude performed by recrystallization afforded compound 12c (72mg, 36 %) as a white 
solid.  
1H-NMR (DMSO-d6): δ 11.35 (1H, broad s, OH), 9.85 (1H, s, NH), 8.67 (1H, s, NH-OH), 7.58 (2H, 
d, J=8.2 Hz, Ar), 7.28 (2H, t, J=8.2 Hz, Ar), 7.02 (1H, t, J=7.4 Hz, Ar), 2.34 – 2.28 (2H, m, CH2), 
1.98 (2H, t, J=7.01 Hz, CH2), 1.55 – 1.54 (4H, m, CH2) 
13C-NMR (DMSO-d6): δ 171.5 (C=O), 169.4 (C=O), 139.7 (Ar, quaternary C), 129.1 (Ar), 123.4 
(Ar), 119.5 (Ar), 36.7 (CH2), 32.6 (CH2), 25.3 (CH2), 25.2 (CH2) 
Melting Point – 193 °C 
FT-IR (ATR): 3177 (O-H), 1655 (C=O), 1630 (C=O) (vmax/cm-1) 
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Experiment 36: Synthesis of [(2‐iodophenyl)carbamoyl]pentanoate (13a) 
 
The procedure in experiment A was applied to adipic acid monomethyl ester (0.2 g, 1.2 mmol). 2-
iodoaniline (1.9 mmol) was used in this experiment. Purification of the reaction mixture by silica 
flash-column chromatography (7:3 hexane-ethyl acetate) afforded compound 13a (412 mg, 94 %) 
as a white solid.  
1H-NMR (CDCl3): δ 8.20 (1H, d, J=7.9 Hz, Ar), 7.77 (1H, d, J=8.0 Hz, Ar), 7.43 (1H, s, NH), 7.34 
(1H, t, J=8.1 Hz, Ar), 6.84 (1H, t, J=7.4 Hz, Ar), 3.68 (3H, s, O-CH3), 2.45 (2H, t, J=6.6 Hz, CH2), 
2.39 (2H, t, J=6.7 Hz, CH2),  1.84 – 1.72 (4H, m, CH2) 
13C-NMR (CDCl3): δ 173.8 (C=O), 171.0 (C=O), 138.7 (Ar), 138.1 (Ar, quaternary C), 129.3 (Ar), 
125.9 (Ar), 122.1 (Ar), 89.2 (I-C, quaternary C), 51.6 (O-CH3), 37.5 (CH2), 33.7 (CH2), 24.9 (CH2), 
24.4 (CH2) 
Melting Point – 64 °C 
FT-IR (ATR): 3260 (N-H), 1728 (C=O), 1655 (C=O) (vmax/cm-1) 
 
Experiment 37: Synthesis of N-hydroxy-N'-(2-iodophenyl)hexanediamide (13c) 
 
The procedure in experiment C was applied to compound 13a (0.15 g, 0.4 mmol). Purification of 
the reaction crude performed by recrystallization afforded compound 13c (97 mg, 65 %) as a 
white solid.  
1H-NMR (DMSO-d6): δ 10.36 (1H, broad s, OH), 9.37 (1H, s, NH), 8.69 (1H, s, NH-OH), 7.87 (2H, 
d, J=7.9 Hz, Ar), 7.45 – 7.35 (2H, m, Ar), 6.98 (2H, t, J=8.1 Hz, Ar), 2.51 – 2.50 (2H, m, CH2), 
1.99 – 1.98(2H, m, CH2), 1.59 – 1.57 (4H, m, CH2) 
13C-NMR (DMSO-d6): δ 171.6 (C=O), 169.4 (C=O), 140.1 (Ar, quaternary C), 137.8 (Ar), 129.1 
(Ar), 128.1 (Ar), 121.7 (Ar), 97.3 (I-C, quaternary C), 36.7 (CH2), 32.6 (CH2), 25.3 (CH2), 25.2 
(CH2) 
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Melting Point – 112 °C 
FT-IR (ATR): 3237 (O-H), 1648 (C=O), 1625 (C=O) (vmax/cm-1) 
 
Experiment 38: Synthesis of [(4‐iodophenyl)carbamoyl]pentanoate (14a) 
 
The procedure in experiment A was applied to adipic acid monomethyl ester (0.3 g, 1.9 mmol). 4-
iodoaniline (2.8 mmol) was used in this experiment. Purification of the reaction crude performed 
by recrystallization afforded compound 14a (647 mg, 96 %) as a white solid.  
1H-NMR (CDCl3): δ 7.61 (2H, d, J=8.8 Hz, Ar), 7.41 (1H, broad s, NH), 7.33 (2H, d, J=8.7 Hz, Ar), 
3.69 (3H, s, O-CH3), 2.38 (4H, t, J=6.9 Hz, CH2), 1.79 – 1.67 (4H, m, CH2) 
13C-NMR (CDCl3): δ 179.8 (C=O), 173.1 (C=O), 137.8 (Ar), 137.4 (Ar, quaternary C), 121.0 (Ar), 
86.1 (I-C, quaternary C), 51.9 (O-CH3), 37.5 (CH2), 32.9 (CH2), 27.0 (CH2), 24.4 (CH2) 
Melting Point – 130 °C 
FT-IR (ATR): 3358 (N-H), 1720 (C=O), 1692 (C=O) (vmax/cm-1) 
 
Experiment 39: Synthesis of 5-[(4-iodophenyl)carbamoyl]pentanoic acid (14b) 
 
The procedure in experiment B was applied to compound 14a (50 mg, 0.1 mmol). Purification of 
the reaction crude performed by recrystallization afforded compound 14b (42 mg, 88 %) as a 
white solid.  
1H-NMR (DMSO-d6): δ 11.8 (1H, broad s, OH), 9.99 (1H, s, NH), 7.61 (2H, d, J=8.7 Hz, Ar), 7.43 
(2H, t, J=8.7 Hz, Ar), 2.30 (2H, t, J=7.2 Hz CH2), 2.23 (2H, t, J=7.3 Hz, CH2), 1.63 – 1.49 (4H, m, 
CH2) 
13C-NMR (DMSO-d6): δ 174.9 (C=O), 171.8 (C=O), 139.6 (Ar, quaternary C), 137.8 (Ar), 121.8 
(Ar), 86.8 (I-C, quaternary C), 36.6 (CH2), 33.9(CH2), 25.0 (CH2), 24.6 (CH2) 
Melting Point – 194 °C 
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FT-IR (ATR): 3291 (O-H), 1687 (C=O), 1655 (C=O) (vmax/cm-1) 
 
Experiment 40: Synthesis of N-hydroxy-N'-(4-iodophenyl)hexanediamide (14c) 
 
The procedure in experiment C was applied to compound 14a (0.25 g, 0.7 mmol). Purification of 
the reaction crude performed by recrystallization afforded compound 14c (38 mg, 15.2 %) as a 
white solid.  
1H-NMR (DMSO-d6): δ 10.36 (1H, broad s, OH), 9.98 (1H, s, NH), 8.68 (1H, s, NH-OH), 7.61 
(2H, d, J=8.8 Hz, Ar), 7.43 (2H, t, J=8.7 Hz, Ar), 2.35 – 2.27 (2H, m, CH2), 1.99 – 1.95 (2H, m, 
CH2), 1.56 – 1.50 (4H, m, CH2) 
13C-NMR (DMSO-d6): δ 171.8 (C=O), 169.4 (C=O), 139.6 (Ar, quaternary C), 137.8 (Ar), 121.7 
(Ar), 86.8 (I-C, quaternary C), 36.5 (CH2), 32.6 (CH2), 25.3 (CH2), 25.1 (CH2) 
Melting Point – 170 °C 
FT-IR (ATR): 3209 (O-H), 1655 (C=O), 1625 (C=O) (vmax/cm-1) 
 
Experiment 41: Synthesis of [(2‐iodophenyl)carbamoyl]heptanoate (15a) 
 
The procedure in experiment A was applied to suberic acid monomethyl ester (0.15 g, 0.8 mmol). 
2-iodoaniline (1.2 mmol) was used in this experiment. Purification of the reaction mixture by flash 
column chromatography (7:3 hexane-ethyl acetate) afforded compound 15a (84 mg, 27 %) as a 
white solid.  
1H-NMR (CDCl3): δ 8.20 (1H, d, J=7.8 Hz, Ar), 7.76 (1H, d, J=7.9 Hz, Ar), 7.45 (1H, broad s, NH), 
7.33 (1H, t, J= 7.8 Hz, Ar), 6.83 (1H, t, J= 7.8 Hz, Ar), 3.66 (3H, s, O-CH3), 2.42 (2H, t, J=7.3 Hz, 
CH2), 2.32 (2H, t, J=7.4 Hz, CH2), 1.81 – 1.73 (2H, m, CH2), 1.69 – 1.61 (2H, m, CH2), 1.45 – 1.35 
(4H, m, CH2) 
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13C-NMR (CDCl3): δ 174.1 (C=O), 171.2 (C=O), 138.8 (Ar), 138.2 (Ar, quaternary C), 129.3 (Ar), 
125.9 (Ar), 123.9 (Ar), 122.1 (Ar), 90.1 (I-C, quaternary C), 51.5 (O-CH3), 37.5 (CH2), 33.8 (CH2), 
24.9 (CH2), 24.4 (CH2) 
 
Experiment 42: Synthesis of N-hydroxy-N'-(2-iodophenyl)octanediamide (15c) 
 
The procedure in experiment C was applied to compound 15a (70 mg, 0.2 mmol). Purification of 
the reaction crude performed by recrystallization afforded compound 15c (47 mg, 67 %) as a 
white solid.  
1H-NMR (DMSO-d6): δ 10.35 (1H, broad s, OH), 9.36 (1H, s, NH), 8.70 (1H, s, NH-OH), 7.87 (1H, 
d, J=7.8 Hz, Ar), 7.40 – 7.35 (2H, m, Ar), 7.01 – 6.96 (1H, m, Ar), 2.32 (2H, t, J= 7.1 Hz, CH2), 
1.95 (2H, t, J= 7.2 Hz, CH2), 1.63 – 1.57 (2H, m, CH2), 1.54 – 1.47 (2H, m, CH2), 1.34 – 1.24 (4H, 
m, CH2) 
13C-NMR (DMSO-d6): δ 179.8 (C=O), 169.9 (C=O),140.6 (Ar, quaternary C), 137.8 (Ar), 127.8 
(Ar), 125.9 (Ar), 123.2 (Ar), 89.2 (I-C, quaternary C), 38.3 (CH2), 32.5 (CH2), 27.9 (CH2), 25.6 
(CH2) 
Melting Point – 128 °C 
FT-IR (ATR): 3275 (O-H), 1659 (C=O), 1620 (C=O) (vmax/cm-1) 
 
Experiment 43: Synthesis of [(4‐iodophenyl)carbamoyl]heptanoate (16a) 
 
The procedure in experiment A was applied to suberic acid monomethyl ester (0.15 g, 0.8 mmol). 
4-iodoaniline (1.2 mmol) was used in this experiment. Purification of the reaction crude performed 
by recrystallization afforded compound 16a (211 mg, 68 %) as a purple solid.  
1H-NMR (CDCl3): δ 7.61 (2H, d, J=8.8 Hz, Ar), 7.31 (2H, d, J=8.7 Hz, Ar), 7.21 (1H, broad s, 
NH),3.67 (3H, s, O-CH3), 2.36 – 2.30 (4H, m, CH2), 1.76 – 1.69 (2H, m, CH2), 1.66 – 1.62 (2H, m, 
CH2), 1.39 – 1.35 (4H, m, CH2)  
39 
 
13C-NMR (CDCl3): δ 179.8 (C=O), 173.1 (C=O), 137.8 (Ar), 137.4 (Ar, quaternary C), 121.0 (Ar), 
86.1 (I-C, quaternary C), 51.9 (O-CH3), 38.3 (CH2), 33.6 (CH2), 28.3 (CH2), 25.0 (CH2) 
Melting Point – 107 °C 
FT-IR (ATR): 3365 (N-H), 1713 (C=O), 1682 (C=O) (vmax/cm-1) 
 
Experiment 44: Synthesis of N-hydroxy-N'-(4-iodophenyl)octanediamide (16c) 
 
The procedure in experiment C was applied to compound 16a (0.15 g, 0.4 mmol). Purification of 
the reaction crude performed by recrystallization afforded compound 16c (31 mg, 21 %) as a 
purple solid.  
1H-NMR (DMSO-d6): δ 10.33 (1H, broad s, OH), 9.96 (1H, s, NH), 8.66 (1H, s, NH-OH), 7.61 (2H, 
d, J=8.6 Hz, Ar), 7.43 (2H, d, J=8.6 Hz, Ar), 2.28 (2H, t, J= 7.4 Hz, CH2), 1.94 (2H, t, J= 7.4 Hz, 
CH2), 1.58 – 1.47 (4H, m, CH2), 1.27 – 1.23 (4H, m, CH2) 
13C-NMR (DMSO-d6): δ 171.9 (C=O), 169.6 (C=O), 139.6 (Ar, quaternary C), 137.8 (Ar), 121.7 
(Ar), 86.7 (I-C, quaternary C), 36.8 (CH2), 32.7 (CH2), 28.8 (CH2), 25.4 (CH2) 
Melting Point – 153 °C 
FT-IR (ATR): 3253 (N-H), 1700 (C=O), 1655 (C=O) (vmax/cm-1) 
 
Experiment 45: Synthesis of [(2‐iodophenyl)carbamoyl]octanoate (17a) 
 
The procedure in experiment A was applied to azelaic acid monomethyl ester (0.25 g, 1.2 mmol). 
2-iodoaniline (1.9 mmol) was used in this experiment. Purification of the reaction crude performed 
by recrystallization afforded compound 17a (94 mg, 19 %) as a white solid.  
1H-NMR (CDCl3): δ 8.21 (1H, d, J=7.8 Hz, Ar), 7.77 (1H, d, J=7.9 Hz, Ar), 7.45 (1H, broad s, NH), 
7.33 (1H, t, J=8.0 Hz, Ar), 6.84 (1H, t, J=7.9 Hz, Ar), 3.66 (3H, s, O-CH3), 2.42 (1H, t, J=7.4 Hz, 
CH2), 2.31 (1H, t, J=7.5 Hz, CH2), 1.79 – 1.72 (2H, m, CH2), 1.67 – 1.59 (2H, m, CH2), 1.42 – 1.32 
(6H, m, CH2) 
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13C-NMR (CDCl3): δ 174.2 (C=O), 171.3 (C=O), 138.8 (Ar), 138.2 (Ar, quaternary C), 129.2 (Ar), 
125.9 (Ar), 122.1 (Ar), 90.0 (I-C, quaternary C), 51.5 (O-CH3), 37.9 (Ar), 34.0 (CH2), 28.9 (CH2), 
25.4 (CH2), 24.9 (CH2) 
Melting Point – 75 °C 
FT-IR (ATR): 3276 (N-H), 1697 (C=O), 1659 (C=O) (vmax/cm-1) 
 
Experiment 46: Synthesis of N-hydroxy-N'-(2-iodophenyl)nonanediamide (17c) 
 
The procedure in experiment C was applied to compound 17a (70 mg, 0.2 mmol). Purification of 
the reaction crude performed by recrystallization afforded compound 17c (37 mg, 53 %) as a 
white solid.  
1H-NMR (DMSO-d6): δ 10.33 (1H, broad s, OH), 9.35 (1H, s, NH), 8.66 (1H, s, NH-OH), 7.87 (1H, 
d, J=7.8 Hz, Ar), 7.41 – 7.35 (2H, m, Ar), 6.98 (1H, t, J=8.1 Hz, Ar), 2.32 (2H, t, J= 7.2 Hz, CH2), 
2.19 (2H, t, J= 7.3 Hz, CH2), 1.63 – 1.60 (2H, m, CH2), 1.54 – 1.49 (2H, m, CH2), 1.35 – 1.26 (6H, 
m, CH2) 
13C-NMR (DMSO-d6): δ 175.0 (C=O), 171.8 (C=O), 140.1 (Ar, quaternary C), 139.3 (Ar), 129.0 
(Ar), 128.0 (Ar), 97.2 (I-C, quaternary C), 36.2 (CH2), 34.2 (CH2), 32.7 (CH2), 28.9 (CH2), 25.6 
(CH2), 24.9 (CH2) 
 
Experiment 47: Synthesis of [(4‐iodophenyl)carbamoyl]octanoate (18a) 
 
The procedure in experiment A was applied to azelaic acid monomethyl ester (0.3 g, 1.5 mmol). 
4-iodoaniline (1.9 mmol) was used in this experiment. Purification of the reaction crude performed 
by recrystallization afforded compound 18a (412 mg, 74 %) as a gray solid.  
1H-NMR (CDCl3): δ 7.61 (2H, d, J=8.6 Hz, Ar), 7.31 (2H, d, J=8.6 Hz, Ar), 7.18 (1H, broad s, NH), 
3.67 (3H, s, O-CH3), 2.35 – 2.29 (4H, m, CH2), 1. 72– 1.60 (4H, m, CH2), 1.39 – 1.32 (6H, m, CH2) 
13C-NMR (CDCl3): δ 179.8 (C=O), 173.1 (C=O), 137.8 (Ar), 137.4 (Ar, quaternary C), 121.0 (Ar), 
86.1 (I-C, quaternary C), 51.9 (O-CH3), 38.3 (Ar), 33.6 (CH2), 29.0 (CH2), 28.6 (CH2), 25.0 (CH2) 
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Melting Point – 87 °C 
FT-IR (ATR): 3309 (N-H), 1724 (C=O), 1690 (C=O) (vmax/cm-1) 
 
Experiment 48: Synthesis of N-hydroxy-N'-(4-iodophenyl)nonanediamide (18c) 
 
 
The procedure in experiment C was applied to compound 18a (0.25 mg, 0.6 mmol). Purification 
of the reaction crude performed by recrystallization afforded compound 18c (112 mg, 45 %) as a 
white solid.  
1H-NMR (DMSO-d6): δ 10.32 (1H, broad s, OH), 9.95 (1H, s, NH), 8.66 (1H, s, NH-OH), 7.43 (2H, 
d, J=8.6 Hz, Ar), 7.21 (2H, d, J=8.7 Hz, Ar), 2.29 (2H, t, J=7.4 Hz, CH2), 2.19 (2H, t, J= 7.5 Hz, 
CH2), 1.58 – 1.47 (4H, m, CH2), 1.30 – 1.25 (6H, m, CH2) 
13C-NMR (DMSO-d6): δ 174.9 (C=O), 171.9 (C=O), 130.6 (Ar, quaternary C), 137.7 (Ar), 121.7 
(Ar), 86.7 (I-C, quaternary C), 36.8 (CH2), 34.1 (CH2), 28.9 (CH2), 25.4 (CH2), 24.9 (CH2) 
Melting Point – 130 °C 
FT-IR (ATR): 3292 (O-H), 1687 (C=O), 1655 (C=O) (vmax/cm-1) 
 
Experiment 49: Attempted synthesis of ethyl (2E)-3-[(2-nitrophenyl)carbamoyl]prop-2-
enoate 
 
The procedure in experiment A was applied to the starting material mono-ethyl fumarate (0.8 g, 
5.5 mmol). 2-nitroaniline (8.3 mmol) was used in this experiment. Purification of the reaction crude 
was performed by recrystallization using hexane and ethyl acetate but the 1H-NMR spectra of the 
reaction product showed only the 2-nitroaniline structure to be present. Therefore, the reaction 
did not occur as expected. 
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Experiment 50: Attempted synthesis of 8‐(phenylcarbamoyl)octanoate 
 
The procedure in experiment A was applied to the azelaic acid monomethyl ester (0.3 g, 1.5 
mmol). Previously distilled aniline (2.2 mmol) was used in this experiment. Purification of the 
reaction crude was performed by recrystallization using hexane and ethyl acetate but 1H-NMR 
spectra did not show the expected structure. Therefore, this reaction did not occur as expected.  
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II.2 Evaluation as anticancer agents 
 
II.2.1 Cancer Cell lines and cell culture: 
The MCF-7 Breast Cancer cell line (ATCC) was cultured in DMEM (Dulbecco's Modified 
Eagle Medium) from Invitrogen, supplemented with Fetal Bovine Serum (FBS) (10%), Glutamax 
(2%), Sodium Pyruvate (1%) and Pen Strep (1%). 
The NCI-H460 Lung Cancer Cell line was cultured in RPMI 1640 medium (Invitrogen) 
supplemented with FBS (10%), Pen Strep (1%) and Puromycin (0.1%), a selection antibiotic.  
Human Dermal Fibroblasts (HDF) (Innoprot) cells were cultured in IMDM (Iscove's 
Modified Dulbecco's Medium) supplemented with FBS (10%) and Pen Strep (1%).  
MCF-7 and H460 cells were sub-cultured twice a week at 1.5x104/cm2. HDF cells were 
sub-cultured once a week at 4x103/cm2. Cells were cultured at 37ºC and 5% CO2 in t-flasks. For 
sub-culture, cells were washed with phosphate-buffered saline (PBS) and then trypsinized using 
0.05% trypsin-EDTA (Invitrogen), for 5 minutes. Viable cell concentration was assessed using 
trypan blue exclusion test. (Section II.2.2). Phase-contrast microscopy of H460, MCF-7 and HDF 
cells was performed using a Leica DMI6000.  
II.2.2 Trypan blue exclusion method  
Viable cells were counted using the trypan blue exclusion method. After incubation with 
a solution 0.1 % of trypan blue dye (Invitrogen), viable cells were counted in a Fuchs–Rosenthal 
hemocytometer chamber under the microscope. Trypan blue is a cell-impermeable dye, so viable 
cells appear colorless while non-viable cells that are membrane damaged are stained by trypan 
blue dye, appearing blue.    
II.2.3 Optimization/implementation of PrestoBlue Cell Viability Assay 
PrestoBlue Cell Viability Reagent (Invitrogen) consists of a resazurin-based solution that 
works as a cell viability indicator. Viable cells are known to maintain a reducing environment in 
their cytoplasm. PrestoBlue reagent contains a blue and nonfluorescent compound that when in 
contact with viable cells is reduced, becoming red and fluorescent. This can be measured by 
fluorescence measurements at 560/590 nm.  
Optimal concentrations for each cell line were assessed by plating cells in 1:2 serial 
dilutions, ranging from 5x103 to 19.50 cells/well for H460 and 1.5x104 to 58 cells/well for MCF-7 
and HDF. Cells were plated in 96 well plates according to the scheme in figure II.8 and cultured 
for 72h. The PrestoBlue viability assay was used as endpoint: cells were incubated for 40 minutes 
with 10 µl of PrestoBlue reagent at 37ºC. After this, 100 µl were collected to a black fluorescence 
reading plate and fluorescence reading was performed in an Infinite 200 PRO NanoQuant plate 
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reader (TECAN) at 560/590 nm. The assay blank consisted of culture medium without cells. 
Calibration Curves were constructed using Graph Pad Prism 6 software. 
 
 
The optimal concentrations chosen for each cell type were: For MCF-7 cell line, 4x103 
cells/well or 1.25x104 cells/cm2, for H460 cell line 2.5x103 cells/ well or 7.8x103 cells/cm2 and for 
HDF 2.5x103 cells/well or 7.8x103 cells/cm2 (See Appendix). These concentrations were used in 
all experiments.   
 
II.2.4 Determination of DMSO toxicity  
Cancer cell lines were treated with a range of DMSO concentrations in order to assess 
DMSO toxicity for each of the cell lines and determine the maximum percentage of DMSO that 
could be used without being harmful to the cells.  
Cells were plated at 7.8x103 cells/cm2 (H460) and 1.25x104 cells/cm2 (MCF-7) in 96 well 
plates and cultured for 24h for cells to adhere to the plate. After that, DMSO was added to the 
cultures and incubated for 48h, at 37ºC. DMSO percentages ranging from 4% to 0.016% were 
tested in a 1:2 serial dilution series, according to the scheme in figure II.9.  The assay control was 
performed with cells in culture medium, without addition of DMSO. PrestoBlue viability assay was 
performed as described in section II.2.3. Values were normalized to the assay control. Dose-
response curves were constructed using Graph Pad Prism 6 software.    
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A                         
B      1.5x104 7.5x103  3.75x103  1.88x103 9.38x102 4.69x102  2.34x102  1.17x102 5.86x101 Blank      
C  1.5x104 7.5x103  3.75x103  1.88x103 9.38x102 4.69x102  2.34x102  1.17x102 5.86x101 Blank   
D  1.5x104 7.5x103  3.75x103  1.88x103 9.38x102 4.69x102  2.34x102  1.17x102 5.86x101 Blank   
E   1.5x104 7.5x103  3.75x103  1.88x103 9.38x102 4.69x102  2.34x102  1.17x102 5.86x101 Blank   
F  1.5x104 7.5x103  3.75x103  1.88x103 9.38x102 4.69x102  2.34x102  1.17x102 5.86x101 Blank   
G  1.5x104 7.5x103  3.75x103  1.88x103  9.38x102 4.69x102    2.34x102  1.17x102  5.86x101 Blank   
H                         
 1 2 3 4 5 6 7 8 9 10 11 12 
A                         
B              5x103  2.5x103 1.25x103   6.25x102   3.13x102   1.56x102  7.81x101 3.91x101    1.95x101   Blank   
C   5x103 2.5x103 1.25x103   6.25x102  3.13x102   1.56x102  7.81x101 3.91x101   1.95x101   Blank   
D   5x103 2.5x103 1.25x103   6.25x102  3.13x102   1.56x102  7.81x101 3.91x101   1.95x101   Blank   
E   5x103 2.5x103 1.25x103   6.25x102  3.13x102   1.56x102  7.81x101 3.91x101   1.95x101   Blank   
F   5x103 2.5x103 1.25x103   6.25x102  3.13x102   1.56x102  7.81x101 3.91x101   1.95x101   Blank   
G   5x103  2.5x103 1.25x103    6.25x102   3.13x102    1.56x102  7.81x101  3.91x101   1.95x101   Blank   
H                         
Figure II.8 – Plate schemes for implementation/optimization of PrestoBlue cell viability assay.  
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Figure II.9 – Plate scheme for determination of DMSO toxicity with % of DMSO tested. Control without 
DMSO (CTRL) 
  
II.2.5 Dose-response curves of SAHA  
SAHA (Sigma-Aldrich, Ref SMC0061) was dissolved in DMSO at a concentration of 50 
mM and aliquots were stored at -20ºC.  The compound was added to the cancer cell lines at 
different concentrations in order to study its effect on cell viability, generate dose response curves 
and calculate the IC50 (half maximal inhibitory concentration). IC50 is a key concept in 
pharmacology and is commonly referred to as the half-maximal inhibitory concentration. It works 
as a measure of the effectiveness of a compound in inhibiting a biological or biochemical function. 
This quantitative measure indicates how much of a particular drug is needed to inhibit a given 
biological process by half. 
Cells were plated at 7.8x103 cells/cm2 (H460) and 1.25x104 cells/cm2 (MCF-7) in 96 well 
plates and cultured for 24h in 100 µl of culture medium. SAHA concentrations tested ranged from 
0.5 mM to 5pM, in a media matrix with 0.9% DMSO, according to the scheme in figure II.10. To 
prepare this, SAHA compound was diluted in culture medium at a concentration of 1 mM and 1:10 
serial dilutions were performed in culture medium with 1.8% DMSO. 100µl of each SAHA dilution 
was then added to each well of the culture plate. Cells were exposed to SAHA for 48h at 37ºC, 
after which Presto Blue viability assay was performed as described in section II.2.3. Dose-
response curves were constructed using Graph Pad Prism 6 software.  
Figure II.10 – Plate scheme for dose-response curve of SAHA with concentrations of SAHA tested.  
 
1 2 3 4 5 6 7 8 9 10 11 12 
A                         
B              4% 2% 1% 0.5% 0.25% 0.125% 0.063% 0.030% 0.016% CTRL   
C   4% 2% 1% 0.5% 0.25% 0.125% 0.063% 0.030% 0.016% CTRL   
D   4% 2% 1% 0.5% 0.25% 0.125% 0.063% 0.030% 0.016% CTRL   
E   4% 2% 1% 0.5% 0.25% 0.125% 0.063% 0.030% 0.016% CTRL   
F   4% 2% 1% 0.5% 0.25% 0.125% 0.063% 0.030% 0.016%  CTRL   
G   4% 2% 1% 0.5% 0.25% 0.125% 0.063% 0.030% 0.016% CTRL   
H                         
 
1 2 3 4 5 6 7 8 9 10 11 12 
A                         
B              0.5 mM 50 µM 5 µM 0.5 µM 50 nM 5 nM 0.5 nM 50 pM 5 pM CTRL   
C   0.5 mM 50 µM 5 µM 0.5 µM 50 nM 5 nM 0.5 nM 50 pM 5 pM CTRL   
D   0.5 mM 50 µM 5 µM 0.5 µM 50 nM 5 nM 0.5 nM 50 pM 5 pM CTRL   
E   0.5 mM 50 µM 5 µM 0.5 µM 50 nM 5 nM 0.5 nM 50 pM 5 pM CTRL   
F   0.5 mM 50 µM 5 µM 0.5 µM 50 nM 5 nM 0.5 nM 50 pM 5 pM CTRL   
G   0.5 mM 50 µM 5 µM 0.5 µM 50 nM 5 nM 0.5 nM 50 pM 5 pM CTRL   
H                         
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II.2.6 Drug Testing   
Drug testing was performed using cell viability as endpoint measured by Presto Blue 
viability assay. Lung (H460) and breast (MCF-7) cancer cell lines were exposed to the newly 
synthesized compounds (Table III.3.B) and SAHA was used as a reference compound. Also, 
human dermal fibroblasts (HDF) were exposed to SAHA and synthesized compounds 15c and 
16c, in order to test the effect of these molecules in normal/non-transformed cells. Cells were 
plated at 1.25x104 cells/cm2 for MCF-7 and 7.81x103 cells/cm2 for H460 and HDF 24h prior to the 
assay, in order for cells to adhere. Compounds were added to the plates in three different 
concentrations (500, 50 and 5µM), according to the scheme in figure II.11 and incubated for 48h 
at 37ºC.  Presto Blue viability assay was performed as described in section II.2.3. 
All compound concentrations were assayed in a matrix of culture medium with 0.9% 
DMSO (in cells) and DMSO controls used in all experiments. Values were normalized to DMSO 
controls. Data Graphs were constructed using Graph Pad Prism 6 software.   
 
 
 
 
Figure II.11 - Plate scheme for drug testing of all compounds with concentrations tested. 
 
 
II.2.7 Apoptosis Assay using NucView 
 
In order to assess if SAHA and Compound 16c were able to induce apoptosis in MCF-7 
breast cancer cell line, levels of apoptotic cells were determined using fluorescence labelling with 
a caspase probe (NucView) followed by flow cytometry. Caspase-3 activation is an early event 
and initiates apoptotic damage. Therefore, early stage apoptosis in cells can be accessed 
measuring levels of caspase-3. The Apoptosis Assay Kit NucView™ 488 (Biotium) consists of a 
DNA dye and a substrate moiety specific for caspase-3. Initially, the substrate is nonfunctional as 
a DNA dye and not fluorescent. The substrate crosses the cell membrane and in cytoplasm is 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A                         
B              500 µM 50 µM 5 µM 500 µM 50 µM 5 µM 500 µM 50 µM 5 µM CTRL   
C   500 µM 50 µM 5 µM 500 µM 50 µM 5 µM 500 µM 50 µM 5 µM CTRL   
D   500 µM 50 µM 5 µM 500 µM 50 µM 5 µM 500 µM 50 µM 5 µM CTRL   
E   500 µM 50 µM 5 µM 500 µM 50 µM 5 µM 500 µM 50 µM 5 µM CTRL   
F   500 µM 50 µM 5 µM 500 µM 50 µM 5 µM 500 µM 50 µM 5 µM CTRL   
G   500 µM 50 µM 5 µM 500 µM 50 µM 5 µM 500 µM 50 µM 5 µM CTRL   
H                         
Compound A Compound C 
 
Compound B 
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cleaved by caspase-3 forming a high-affinity DNA dye. After migration to the cell nucleus, the 
DNA dye is able to stain the nucleus with bright green fluorescence35.  
 
Cells were plated at 1.25x104 cells/cm2 in 6 well plates and cultured for 24h. SAHA and 
Compound 16c were added to the cells at 50 µM and incubated for 48h at 37ºC. DMSO control 
was obtained by adding the same percentage of DMSO present in drug incubations to cells from 
an independent well. After the incubation time, cells were trypsinized (0.05% trypsin-EDTA) and 
collected. Cells (0.2-0.5x106) were centrifuged for 5 minutes at 300x g, at room temperature. After 
removal of the supernatant, the cell pellet was resuspended in 200µl of medium containing 1µl of 
NucView reagent and incubated for 1 hour at 37ºC. Cells were centrifuged at 300x g for 5 minutes 
and resuspended in 500µl of PBS for analysis by flow cytometry (CyFlow Space, Partec, 
Germany). Flow cytometry results were analysed using FlowJo software. 
 
 
II.2.8 Cell Cycle analysis 
 
In order to access if SAHA and Compound 16c were able to induce cell cycle arrest in 
MCF-7 breast cancer cell line, cell cycle analysis was performed using fluorescence labelling and 
flow cytometry. The cell cycle is characterized by consecutive events that take place in a cell 
leading to its division and duplication with the final goal of producing two daughter cells. It is 
possible to distinguish cells in different phases of the cell cycle by the amount of DNA present in 
the cell because during cell cycle DNA replication occurs. By labelling the cell DNA with a DNA 
intercalating probe such as propidium iodide (PI), correlation between fluorescence intensity and 
the amount of DNA present in the cell can be made. So, cells in phase G2/M which contain two 
copies of DNA will have the twice the fluorescence intensity when compared with cells in G1 
phase that only have one copy of DNA. Cells in phase S will show an intermediate fluorescence36.  
This protocol for cell cycle analysis is based on findings published by Vindelov in 197737. 
In his work, he was able to optimize the nuclei staining solution and their components. Up to date, 
the solution used for nuclei staining is called Vindelov´s solution and is composed of 1 g/L trisodic 
citrate, pH 7.6 (Sigma); 50 mg/L propidium iodide (Sigma); 0.1% NP 40 (Roche); 0.700 U/mL 
Ribonuclease A (Sigma) and 0.01 M NaCl (Merck). There are other different protocols for cell 
cycle analysis but this one was already optimized in the laboratory by previous colleagues and 
therefore was used in this experiment.  
 
Cells were plated at 1.25x104 cells/cm2 in 6 well plates and cultured for 24h. SAHA and 
Compound 16c were added to the cells at 50 µM and cells incubated for 48h at 37ºC. After 
incubation time, cells were trypsinized (0.05% trypsin-EDTA) and collected. Cells (1×106cells) 
were centrifuged for 5 min at 500x g at room temperature and washed by resuspension in PBS. 
After another centrifugation step, cells were resuspendend in 1ml of Vindelov´s solution and 
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incubated at room temperature for 2 hours. Next, cells were incubated overnight at 4ºC, and 
analysed by flow cytometry (CyFlow Space, Partec, Germany). 
DMSO control was obtained by adding the same percentage of DMSO present in drug incubations 
to cells from an independent well. Data results were analysed using FlowJo software.  
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III. RESULTS AND DISCUSSION 
 
III.1 Synthesis of new HDACi 
 
Overall, 48 compounds were successfully synthesized (Table III.3) and 30 of them were 
used for further analysis in cancer cell lines (Table III.3-B).  
In a first round of synthesis the linker 4 carbons long and a trans double bond was 
preserved (linker more similar to Belinostat). To this end, mono-ethyl fumarate was used as 
starting reagent in the first step of synthesis. Different aniline derivatives were used in order to 
obtain diverse capping groups for these compounds, where the aromatic ring has different atoms 
attached at different positions.  
After the testing of these compounds (See section III.2.4.1) analysis of the results led to 
a second round of synthesis were the changes in capping group that led to a higher effect were 
kept, and compounds with other linkers (different carbon lengths) were synthesized. To achieve 
this, adipic acid monomethyl ester, suberic acid monomethyl ester and azelaic acid monomethyl 
ester were used as starting materials for the amide formation reaction. That enabled the synthesis 
of compounds with 6, 8 and 9 carbon chains in their linker, respectively. (The 8 carbon chain 
linker is equal to that found in SAHA structure).   
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Table III.3 - Structures of all synthesized compounds with respective numerations. 
Table III.3.A - Ester intermediates obtained from 1st step of synthesis. 
COMPOUND STRUCTURE COMPOUND STRUCTURE 
1a 
 
10a 
 
2a 
 
11a 
 
3a 
 
12a 
 
4a 
 
13a 
 
5a 
 
14a 
 
6a 
 
15a 
 
7a 
 
16a 
 
8a 
 
17a 
 
9a 
 
18a 
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Table III.3.B - Carboxylic and hydroxamic derivatives synthesized - Compounds tested in cancer cell lines. 
 
COMPOUND STRUCTURE COMPOUND STRUCTURE 
 
1b  
 
5b 
 
 
1c 
 
 
5c 
 
 
2b  
 
6b 
 
 
2c 
 
 
6c 
 
 
3b  
 
7b 
 
 
3c 
 
 
7c 
 
 
4b 
 
 
8b 
 
 
4c 
 
 
8c 
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COMPOUND STRUCTURE COMPOUND STRUCTURE 
9b 
 
 
 
13c 
 
9c 
 
 
 
14b  
10b 
  
14c 
 
10c 
 
15c  
 
11b 
 
16c 
 
11c 
 
17c 
 
 
12c 
 
18c  
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 III.1.2 Results from the 1st round of synthesis  
 
Table III.4 – 1st step of the synthesis using mono-ethyl fumarate as starting material and several anilines. 
The table describes the compounds obtained (respective numbering) and corresponding yields.  
 
 
 
 
 
R1 R2 Position Aniline used Compound Yield (%) 
- - - Aniline (Merck) 1a 73 
F 
- ortho 2-Fluoroaniline (Aldrich) 5a 52 
- para 4-Fluoroaniline (Fluka) 2a 74 
Br Br-ortho 
F-para 
2-Bromo-4-fluoroaniline 
(Aldrich) 
7a 38 
Br 
- ortho 2-Bromoaniline (Aldrich) 3a 41 
- para 4-Bromoaniline (Aldrich) 4a 90 
Cl - ortho 2-chloroaniline (Aldrich) 6a 54 
F3C 
- 
para 
4-(Trifluoromethyl)aniline 
(Aldrich) 
8a 71 
OCH3 
- 
meta 
3-Methoxyaniline 
(Aldrich) 
9a 70 
I 
- Ortho 2-iodoaniline (TCI) 10a 48 
- Para 4-iodoaniline (Alfa Aesar) 11a 80 
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Table III.5 – Synthesis of carboxylic acid derivatives from compounds present in table III.4. The table 
describes the compounds obtained (respective numbering) and corresponding yields. 
 
 
R1 R2 Position Compound Yield (%) 
- - - 1b 26 
F 
- ortho 5b 74 
- para 2b 27 
Br 
Br-ortho 
F-para 
7b 89 
Br 
- ortho 3b 49 
- para 4b 74 
Cl - ortho 6b 88 
F3C - para 8b 70 
OCH3 - meta 9b 89 
I 
- ortho 10b 97 
- para 11b 88 
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Table III.6 - Synthesis of hydroxamic acid derivatives from compounds present in table III.4. The table 
describes the compounds obtained (respective numbering) and related yields. 
 
 
R1 R2 Position Compound Yield (%) 
- - - 1c 43 
F 
- ortho 5c 37 
- para 2c 39 
Br 
Br-ortho 
F-para 
7c 27 
Br 
- ortho 3c 51 
- para 4c 29 
Cl - ortho 6c 25 
F3C - para 8c 98 
OCH3 - meta 9c 15 
I 
- ortho 10c 42 
- para 11c 31 
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III.1.3 Results from the 2nd round of synthesis  
 
Table III.7 - 1st Step of the synthesis using adipic acid monomethyl ester as starting material and several 
anilines. The table describes compounds obtained (respective numbering) and corresponding yields. 
               
R1 Position Aniline used Compound Yield (%) 
- - Aniline 12a 94 
I 
ortho 2-iodoaniline (TCI) 13a 82 
para 4-iodoaniline (Alfa Aesar) 14a 96 
 
 
Table III.8 - Synthesis of carboxylic acid derivative 14b.   
 
 
 
 
Compound Yield (%) 
14b 88 
 
 
 
 
 
14a 14b 
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Table III.9 - Synthesis of hydroxamic acid derivatives from compounds present in table III.7. The table 
describes the compounds obtained (respective numbering) and corresponding yields. 
 
 
 
 
R1 Position Compound Yield (%) 
- - 12c 36 
I 
ortho 13c 65 
para 14c 15 
 
 
 
Table III.10 - 1st Step of the synthesis using suberic acid monomethyl ester as starting material and several 
anilines. The table describes the compounds obtained (respective numbering) and corresponding yields.  
 
R1 Position Aniline used Compound Yield (%) 
I 
ortho 2-iodoaniline (TCI) 15a 27 
para 4-iodoaniline (Alfa Aesar) 16a 68 
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Table III.11 - Synthesis of hydroxamic acid derivatives from compounds present in table III.10. The table 
describes the compounds obtained (respective numbering) and corresponding yields. 
 
R1 Position Compound Yield (%) 
I 
ortho 15c 67 
para 16c 21 
 
 
Table III.12 - 1st Step of the synthesis using azelaic acid monomethyl ester as starting material and several 
anilines. The table describes compounds obtained (respective numbering) and corresponding yields. 
 
R1 Position Aniline used Compound Yield (%) 
I 
ortho 2-iodoaniline (TCI) 17a 19 
para 4-iodoaniline (Alfa Aesar) 18a 74 
 
 
Table III.13 - Synthesis of hydroxamic derivatives from compounds present in table III.12. The table 
describes the compounds obtained (respective numbering) and corresponding yields. 
 
R1 Position Compound Yield (%) 
I 
ortho 17c 53 
para 18c 45 
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III.1.4 Discussion  
 
Analyzing the yields of the compounds from the amide formation (1st step reaction), the 
amides were obtained in 19-96% yields. Carboxylic acid derivatives were obtained with 26-97% 
yields and hydroxamic acids were obtained with 15-98% yields.  
In the reaction where carboxylic acids are formed, optimizations were introduced during 
the work up: addition of one more step of washing the ethyl ether phase with water and an 
acidification to a more acidic pH (closer to 3). These changes led to higher yields in comparison 
with first reactions where these changes were not implemented. (See table III.5 – section III.1.2)  
Hydroxamic acids are normally obtained with a lower yield compared with the other steps. 
This is because under the reaction conditions used, NaOH is present and can hydrolyse the ester 
group to a carboxylic acid group. This by-product can be removed by washing the reaction mixture 
with sodium bicarbonate, but its formation lowers the yield of the desired hydroxamic acid product.  
In the literature, similar reactions showed 10-90% yield32. Optimizations were performed in order 
to achieve higher yields with an addition of a higher quantity of NH2OH.HCl to the mixture but the 
yields were not improved. Compound 9c (See figure III.12), was firstly obtained as a mixture with 
the corresponding carboxylic acid (9b), as can be seen in the top proton NMR spectrum. After 
washing with sodium bicarbonate the carboxylic acid was removed as its sodium salt, leaving the 
hydroxamic acid 9c pure (middle proton NMR spectrum). 
 
 
Figure III.12 – 1H NMR spectra of compound 9c before (above) and after (below) the sodium bicarbonate 
(NaHCO3) washing step and of compound 9b.  
 
 
Mixture 
9c 
9b 
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In the second round of synthesis, the use of different starting materials with longer carbon 
chain lengths led to methyl ester products that were not solid after work-up. Therefore, some 
compounds (12a, 13a and 15a) were purified using silica flash chromatography instead of 
recrystallization. Nevertheless, all synthesized compounds were solid after purification.  
As mentioned before (section I.4.4), other compounds can be used as carboxyl-activating 
agents in coupling reactions such as N,N'-dicyclohexylcarbodiimide (DCC) and N,N'-
diisopropylcarbodiimide (DIC). A small scale synthesis using DIC and DCC was performed in 
order to assess which is the better coupling agent and which leads to better yields. Reaction using 
DCC led to addition of more steps in work-up (filtration using celite), a lower yield comparing to 
when EDC is used, and impurities present in NMR spectra. Also, DCC can cause allergies 
therefore extra care is needed in handling this reagent. Reaction using DIC also led to a lower 
yield compared to when EDC is used. For these reasons, EDC was chosen as the best reagent 
to act as reaction activator and was used in all syntheses. 
It is quite difficult to distinguish between carboxylic and hydroxamic acids where the rest 
of the structure is identical, even using NMR spectroscopy. Analysis of 1H-NMR spectra 
comparing carboxylic acid and hydroxamic acid derivatives presented a shift of the peaks related 
to protons closer to the carbonyl groups. (See figure III.13).  
                        
 
 
Figure III.13 - 1H NMR spectra of compounds 14b (above) and 14c (below). In both spectra, the area 
important to distinguish between both derivatives is highlighted. At the top are the structures of compounds 
14b and 14c, respectively.  
 
14b 14c 
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The peaks highlighted in both spectra are related to the protons closer to the carbonyl 
groups (indicated by arrows in both structures). Comparing the two structures, in the carboxylic 
acid these peaks are closer together than in the hydroxamic acids. During the analysis of several 
spectra it was possible to see that this feature (more separated peaks) is preserved even in 
hydroxamic acids with different substituents in the benzenic ring.   
It was possible to see differences between 1H-NMR spectra of carboxylic and hydroxamic 
acids also in the compounds obtained in the first round of synthesis, in peaks related to protons 
present in the double bond. (See figure III.14) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.14 - 1H NMR spectra of compounds 4c, 4b, 2c and 2b, respectively. Structures of the compounds 
at the right of each spectrum.  
 
Comparing the 1H-NMR spectra, a shift of the peaks related to the protons of the double 
bond can be observed (see figure III.14). In similar way as described before, these peaks (see 
arrows in the figure) are much closer together in hydroxamic acids and farther apart in carboxylic 
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acids. This was observed in several compounds, even with different atoms at different positions 
in the aromatic ring (examples in figure III.14).  
Compound structures were confirmed by NMR spectroscopy before performing biological 
assays. All ester compounds obtained from the 1st step of synthesis were dissolved in CDCl3 for 
NMR spectroscopy while carboxylic and hydroxamic acids were dissolved in DMSO-d6.  
All tested compounds (table III.3.B) and also SAHA were dissolved in DMSO at a 
concentration of 50 mM taking into account the SAHA solubility in DMSO (≥15 mg/mL). 
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III.2 New HDACi evaluation as anticancer agents 
 
For the evaluation of the newly synthesized compounds as anticancer agents, two 
different cancer cell lines were used: MCF-7, a breast cancer cell line and H460, a lung cancer 
cell line. (See figure III.15).  
 
 
Figure III.15 - Phase-contrast microscopy of H460 cells (left) and MCF-7 cells (right). Scale bars 
represents 100 µm. 
 
Also, HDF (Human Dermal Fibroblasts) were used as a normal cell model for testing the 
effect of SAHA, compound 15c and compound 16c in cell viability of non-malignant cells (See 
figure III.16).  
 
 
Figure III.16 - Phase-contrast microscopy of Human Dermal Fibroblasts. Scale bar represents 100 µm. 
 
 
 
MCF-7 H460 
HDF 
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III.2.1 Determination of DMSO toxicity  
 
All compounds, including the positive control SAHA, were dissolved in DMSO. DMSO has 
been shown to be toxic to mammalian cells, even at low concentrations 38. DMSO toxicity for each 
of the cell lines used in this study was assessed by treating MCF-7 and H460 cells with a range 
of DMSO concentrations (0.016 to 4%).   
The dose-response curves obtained are presented in Figure III.17.  
 
 
 
 
 
 
 
 
 
 
 
Figure III.17 – Dose-response curves for DMSO for each cancer cell line (MCF-7 and H460). Dose-response 
curves were generated using Graph Pad Prism 6 software. 
 
DMSO percentages of 4% and 2% had a clearly effect on cell viability of both cancer cell 
lines, causing a decrease in the percentage of live cells, higher than 25% for MCF-7 cells and 
50% for H460 cells. The H460 cell line seems to be more sensitive to DMSO than MCF-7, as it 
presented a higher toxicity (lower percentages of live cells comparing to MCF-7) at 4% and 2%. 
For DMSO percentages below 1%, cell viability was not affected, with cell viabilities of 
approximately 100%. Therefore, 1% DMSO was chosen as the maximum of DMSO to be used in 
further assays. 
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III.2.2 Drug Testing   
 
III.2.2.1 1ST round Compounds Testing 
All compounds obtained in the first round of synthesis were tested on cancer cell lines 
(MCF-7 and H460) using cell viability as end-point. SAHA was used as positive control in the drug 
testing assays because it is an HDACi already approved as anticancer drug and the new 
synthesized compounds are structurally similar. To assess SAHA anticancer affect in the 
implemented assay set-up, the compound was added to each of the cancer cell lines at three 
different concentrations: 500 µM, 50 µM and 5 µM, and was incubated for 48h, after which cell 
viability was measured using the PrestoBlue Assay (See figure III.18). 
*
[S A H A ] (M )
C
e
ll
 V
ia
b
il
it
y
 (
%
 o
f 
v
ia
b
le
 c
e
ll
s
 t
o
 u
n
tr
e
a
te
d
 c
o
n
tr
o
l)
5
0
0
 
M
5
0
 
M
5
 
M
5
0
0
 
M
5
0
 
M
5
 
M
0
2 0
4 0
6 0
8 0
1 0 0
M C F -7
H 460
* * * *
* * * *
*
* * *
* *
 
Figure III.18 - Effect of SAHA on MCF-7 and H460 cell viability, determined by PrestoBlue assay. Both 
cancer cells lines were treated with three different concentrations of SAHA: 500 50 and 5 µM, for 48h. Data 
are mean ± SD of three independent experiments; asterisks indicate significant difference to negative control 
(*p≤0.05, **p≤0.01, ***p≤0.001 and ****p≤0.0001) by one-way ANOVA analysis with Kruskal-Wallis 
comparison test. Graph constructed using Graph Pad Prism 6 software. 
Analyzing the results, a negative effect of SAHA on cell viability in both cancer cell lines 
is observed. Addition of SAHA to the cultures led to a decrease in cell viability in all three 
concentrations tested, in a dose-dependent manner.  
 For H460 cells, 5 µM of SAHA led to a significant reduction in cell viability to 50 ±7.5%, 
which is in line with the IC50 of 2.3 µM previously reported for this cell line25. On the other hand, 
5 µM of SAHA only led to a reduction in MCF-7 cell viability to 80 ±7.2%, despite the previous 
report of an IC50 of 0.75 µM for this cell line39. P. Munster et al calculated an IC50 of 0.75 µM 
after 120h of continuous exposure to SAHA and in this experiment MCF-7 cells were treated with 
SAHA for 48h which can explain the differences in IC50. Alternatively, this result can be due to 
differences between lots of MCF-7 cells. It has been reported in some studies that MCF-7 cells, 
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even from the same frozen batch, can present genetic variations and this heterogeneity can have 
serious consequences for the reproducibility of experiments40.  
SAHA and similar HDACi have an antiproliferative effect in malignant cells19. The results 
obtained suggest that the H460 cell line presents higher sensitivity to SAHA action, and the fact 
that this cell line is more proliferative than MCF-7 could explain this result. 
 
 
The newly synthesized compounds (see section III.1.2) were also tested in both cancer 
cell lines, using the same assay set-up. As described in section III.1, in the first generation of 
hydroxamic acid compounds, the linker was kept constant and the capping group was altered, 
with the addition of different atoms or groups to the benzenic ring in different positions. The 
atoms/groups added were: -F, -Br, -I, -F3C, -OCH3, and Cl. Synthesis of a compound without any 
atom addition to benzenic ring (1c) and a compound with addition of both fluorine and bromine 
atoms was also performed successfully (7c). (See table 3.B for the compounds structure.) 
The drug assays of all hydroxamic acid compounds synthesized are presented in figure 
III.19. 
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Figure III.19 - Effect of SAHA and the hydroxamic compounds synthesized in the 1st round of synthesis on 
MCF-7 and H460 cell viability, determined by PrestoBlue assay. Both cancer cells lines were treated with 
three different concentrations of SAHA: 500, 50 and 5 µM, for 48h. Data are mean ± SD of two independent 
experiments; asterisks indicate significant difference to negative control (*p≤0.05, **p≤0.01, ***p≤0.001 and 
****p≤0.0001) by one-way ANOVA analysis with Kruskal-Wallis comparison test. Graph constructed using 
Graph Pad Prism 6 software. 
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All tested hydroxamic acid compounds had a negative effect on cell viability in both breast 
and lung cancer cells, mainly at 500 µM. In H460 cell line, compounds 10c, 11c, and 8c showed 
a significant reduction in cell viability even at 50 µM. However, none of the new compounds tested 
had an effect comparable to SAHA.  
The changes in capping group made in the analogues produced did not improve the toxic 
effect in MCF-7 and H460 cells. In general, the first generation hydroxamic compounds showed 
a higher effect in H460 cells than in MCF-7 cells, similarly to what was observed for SAHA.  
Interestingly compound 1c (Figure III.21), that only differs from SAHA in terms of the 
length of the linker (see SAHA structure in section I.4.2), presented a weaker effect when 
compared to SAHA in both cancer cells lines (65.2 ± 9 % vs 25 ± 5 % of cell viability for 500 µM 
concentration in MCF-7 and 61.2 ± 10 % vs 10.3 ± 5 % of cell viability for 500 µM concentration 
in H460). This result suggested that linker size present in SAHA could be critical to the effect of 
this type of compounds in cancer cell lines and led to the hypothesis that spacers with longer 
carbon lengths (more similar to SAHA) could lead to more effective compounds.   
Taking into account the results for all the atomic substitutions, the ortho position 
(compounds 5c, 3c and 10c), seems to favor a higher effect in cell viability, compared with 
additions of the same atom in another positions.  
As for the atom itself, compounds with iodine resulted in the higher decrement in cell 
concentration. Compound 10c, with iodine in ortho position, was the best candidate from the first 
generation compounds, presenting an effect closer to SAHA at 500 µM. (19 ± 3% vs 10 ± 5%, 
respectively).  
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The results concerning the effect of the synthesized carboxylic acids are presented in 
Figure III.20.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.20 –  Effect of SAHA and the carboxylic compounds synthesized in the 1st round of synthesis on 
MCF-7 and H460 cell viability, determined by PrestoBlue assay. Both cancer cells lines were treated with 
three different concentrations of SAHA: 500, 50 and 5 µM, for 48h. Data are mean ± SD of two independent 
experiments; asterisks indicate significant difference to negative control (*p≤0.05, **p≤0.01, ***p≤0.001 and 
****p≤0.0001) by one-way ANOVA analysis with Kruskal-Wallis comparison test. Graph constructed using 
Graph Pad Prism 6 software. 
 
None of the compounds showed a negative effect in cell viability, at any of the 
concentrations tested. So, the results suggest that the hydroxamic acid moiety is essential for the 
action of these compounds as anticancer drugs. Indeed, the hydroxamic acid moiety has been 
proposed to be critical for the HDAC inhibitory activity, working as a metal chelator that  interacts 
with the zinc present in the active pocket of HDAC enzymes34.  Although carboxylic acids are also 
metal chelators, they are not as strong as hydroxamic, which may explain the lack of activity of 
compounds with carboxylic moieties.  
 
In summary, the hydroxamic acids synthesized had a negative impact on cell viability of 
the cancer cell lines tested, contrary to the carboxylic acids, that showed no effect in both breast 
and lung cancer cells. None of the tested compounds showed an effect comparable to SAHA, 
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indicating that the structure modifications did not lead to a more potent compound. The results 
suggested that the linker length is probably very important for the anticancer effect and that the 
substitution in the benzene ring in an ortho position, especially with iodine, can potentially 
generate compounds with improved potency.  
 
Taking into account these observations, a new series of analogues was planned, 
including hydroxamic acid derivatives with longer carbon chains as linkers - 6, 8 and 9 carbon 
long chains; with iodine atoms added to the benzenic ring in not only in the ortho but also in the 
para position.  
 
A carboxylic acid compound (14b) and a compound without any addition to benzene (12c) 
were also synthesized with a longer carbon chain in order to evaluate if the previous results are 
maintained when the linker is altered.  
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III.2.2.2 2ND round Compounds Testing  
 
After successful synthesis of the new compounds (See section III.1.3), these molecules 
were tested in MCF-7 and H460 cells, and cell viability was assessed (Figure III.21).  
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Figure III.21 – Effect of SAHA and all compounds synthesized in the 2nd round of synthesis on MCF-7 and 
H460 cell viability, determined by PrestoBlue assay. Both cancer cells lines were treated with three different 
concentrations of SAHA: 500, 50 and 5 µM, for 48h. Data are mean ± SD of two independent experiments; 
asterisks indicate significant difference to negative control (*p≤0.05, **p≤0.01, ***p≤0.001 and ****p≤0.0001)  
by one-way ANOVA analysis with Kruskal-Wallis comparison test. Graph constructed using Graph Pad 
Prism 6 software. 
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Compound 16c showed a significant reduction in cell viability of both MCF-7 and H460 
cells, higher than SAHA especially at 50 µM. (26.5 ± 6 % vs 58.4 ± 6 %, for MCF-7, respectively 
and 11.7 ± 5% vs 38.2 ± 5 % for H460, respectively).   
In H460 cells, 16c showed a significant reduction in cell viability also at 5 µM, and this 
effect is higher than in cells treated with SAHA. (32.9 ± 5% vs 55.2 ± 7%, respectively).  
Compound 15c also showed a significant effect, especially on the H460 cell line at 50 µM 
(33.8 ± 6 %). 
Compound 14b was the only compound tested that had no effect on cell viability, in any 
of the concentration tested, similarly to the carboxylic acids previously tested.  
In general, all compounds tested showed stronger effect on H460 cells than on MCF-7 
and this can be due to the fact that MCF-7 cell line is not so proliferative as H460. 
Both 15c, 16c and SAHA have an 8 carbon chain length as linker, suggesting that the 
linker has the optimal size. Moreover, compound 16c has a structure similar to SAHA, with an 8 
carbon chain as a linker and a hydroxamic acid moiety, but differs only in the presence of an 
iodide atom in the para position of the benzenic ring, suggesting that this substitution can also 
increase the compound activity.  
This result suggests compound 16c as a putative new HDACi with anticancer effects. To 
further evaluate the potential of the compound, further studies are required to address compound 
toxicity in normal cells, o define its mechanisms of action and compare it to already FDA approved 
drugs, like SAHA.   
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III.2.3 Evaluation of Compound 16c    
 
II.2.3.1 Normal Cell resistance  
 
As mentioned before in section I.4.3, HDACi are normally associated with normal cell 
resistance and FDA-approved compounds show antitumor action in cancerous cells at 
concentrations to which normal cells show little toxicity27. HDF were used for testing normal cell 
toxicity of compound 16c, the best candidate from the previous screening. SAHA and compound 
15c were used as controls. Effect on HDF viability was measured using PrestoBlue cell viability 
assay, as before (figure III.22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.22- Effect of SAHA and compound 16c in MCF-7, H460 and HDF cell viability, determined by 
PrestoBlue assay. All cell lines were treated with two different concentrations of SAHA and 16c: 50 and 5 
µM, for 48h. Data are mean ± SD of two independent experiments; asterisks indicate significant difference 
(*p≤0.05 and **p≤0.01) by one-way ANOVA analysis with Kruskal-Wallis comparison test. Graph constructed 
using Graph Pad Prism 6 software.  
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Incubation with compound 16c caused a reduction on HDF viability in all concentrations 
tested. At the lower concentration tested (5 µM), 16c caused a reduction in HDF viability to 52 ± 
8% whereas SAHA and compound 15c had no effect on cell viability.  
These results are consistent with reported findings that normal cells are relatively 
resistant to SAHA-induced cell death. J. Lee at al. reported that after 72 h of culture with 5 μM 
SAHA, there was >80% loss of cell viability of LNCaP (prostate cancer cells) and 30% of A549 
(human lung adenocarcinoma cells), but no detectable loss of cell viability of the normal cells, 
HFS31.  
Also, this result suggests that the presence of an iodine atom in the capping group 
apparently increases the cytotoxic effect of hydroxamic acids in cancer cells (section III.2.4.2), 
when compared to SAHA, but also its cytotoxic effect in normal cells.  
For the lower concentration tested (5 µM), compound 16c had a cytotoxic effect in cancer 
cells approximately twofold higher that SAHA, so it is possible that in a lower concentration range, 
this compound presents the normal cell resistance described for this class of molecules. In the 
future, generation of dose-response curves of compound 16c will be required, to evaluate the 
potency of the compound in cancer cells and normal cell resistance and evaluate if these cells 
present different sensitivities to compound toxicity at lower concentrations.   
 
 
 
 
III.2.3.2 Apoptosis Induction and Cell Cycle Arrest 
 
As mentioned in section I.4.3, the action of SAHA and several HDACi as anti-cancer 
drugs involves their ability to induce/stimulate apoptosis and to induce cell cycle arrest in 
malignant cells6. Therefore, a preliminary evaluation of the capacity of compound 16c to induce 
apoptosis and cell cycle arrest in MCF-7 breast cancer cells was conducted. Apoptosis is 
triggered by caspase activation, and caspase-3 activation is an early event stage apoptosis. 
Therefore, early stage apoptosis can be accessed by measuring caspase-3 levels35. Compound 
16c and SAHA were added to MCF-7 cells at 50 µM and apoptosis was assessed after 48h. 
(Figure III.23).  
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Figure III.23 – Induction of apoptosis by SAHA and Compound 16c. MCF-7 cells were cultured in the 
presence of compound 16c, SAHA or in culture medium with vehicle control (control) for 48h, collected and 
processed for apoptosis analysis using fluorescence labelling with a caspase probe (NucView) followed by 
flow cytometry. 
 
Compound 16c and SAHA induced apoptosis (approximately 29 and 19%, respectively, 
compared with 2% in control). Compound 16c led to a higher induction of apoptosis than SAHA 
however, additional biological replicates are required to draw conclusions on the significance of 
these differences. Nonetheless, the results obtained suggest that compound 16c induces 
apoptosis in MCF-7 cells, as described for SAHA and other HDACi. Hugh et al. observed that 48h 
exposure to 4 µM of SAHA resulted in 20% apoptotic MCF-7 cells41.  
Further studies at additional compound concentrations and including other cancer and 
normal cells are required to corroborate these preliminary results. 
CONTROL 
Compound        
16c 
SAHA 
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In order to assess if compound 16c is able to induce cell cycle arrest in MCF-7 cells, cell 
cycle analysis was performed using flow cytometry and propidium iodide (PI) as intercalating dye. 
(Figure III.24).  
 
 
 
 
 
 
 
Figure III.24 – Cell cycle analysis of MCF-7 cells. MCF-7 cells were cultured in the presence of compound 
16c, SAHA or in culture medium with vehicle control (control) for 48h, collected and processed for cell cycle 
analysis by flow cytometry. Gated region (left), doublet discrimination step (middle) and counted cells in each 
phase of the cell cycle (G1, S and G2/M).   
Control 
SAHA treatment  
16c treatment  
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Figure III.25 – Cell cycle analysis of MCF-7 cells. MCF-7 cells were cultured in the presence of compound 
16c, SAHA or in culture medium with vehicle control (control) for 48h, collected and processed for cell cycle 
analysis by flow cytometry.  
As mentioned in section II.2.8, cells in phase G2/M which contain two copies of DNA will 
have the double of fluorescence intensity when compared with cells in G1 phase that only have 
one copy of DNA. Cells in phase S will show an intermediate fluorescence.  
MCF-7 cells cultured in the presence of vehicle alone (control) showed higher percentage 
of cells in G1 phase of cell cycle (approximately 47%) than in S (approximately 15%) and G2/M 
phase (approximately 29%).  
Histograms of MCF-7 cells treated with SAHA and compound 16c presented broader G1 
peaks when compared with untreated cells.  Apoptotic cells often have fractional DNA due to the 
fact that the fragmented (with low molecular weight) DNA undergoes extraction during the staining 
procedure and they are represented on the DNA content frequency histograms by “sub-G1” 
peaks42.  A high amount of apoptotic cells and “sub-G1” peaks can lead to the appearance of 
broader G1 peaks similarly to the observed in this experiment.  
Cells treated with SAHA presented an increased percentage of cells in G2/M phase, 
compared with cells treated with vehicle control (45% and 29% percent, respectively). These 
results are in agreement with previous literature reports. In published results,  HDACi induced 
G2/M phase arrest, shown by an increase in the percentage of cells in G2/M phase for MCF-7 
cells treated with 4 µM of SAHA after 24h and 48h 41. 
In a similar way, cells treated with compound 16c presented an increased percentage of 
cells in G2/M phase, compared with cells treated with vehicle control (35 % and 29 % percent, 
respectively). 
Therefore, both compounds are able to induce cell cycle arrest at the G2/M phase of cell 
cycle in the MCF-7 breast cancer cell line. This increase is higher for cells treated with SAHA than 
for cells treated with compound 16c, therefore SAHA seems to induce a more severe cell cycle 
arrest than compound 16c in MCF-7 cells.  
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Further studies at additional compound concentrations and including other cancer and 
normal cell lines are required to corroborate these preliminary results.  
 
In summary, compound 16c has a structure similar to SAHA, with an 8 carbon chain as a 
linker and a hydroxamic moiety, but differs in the presence of an iodine atom in the para position 
of the benzenic ring. Results suggested that this substitution increased the compound activity 
towards cancer cell lines but 16c also revealed toxicity against HDF cells. Furthermore, 
preliminary results showed that 16c was able to induce apoptosis and cell cycle arrest at the G2/M 
phase of the cell cycle in the MCF-7 breast cancer cell line. 
It is important to create new drugs, but with an acceptable therapeutic index and useful 
properties. High potency is in general associated with long-term binding of the drug to the 
receptor43.  
In an hydroxamic HDACi such as SAHA, the capping group is important for the interaction 
with the amino acid residues near the entrance of the active site. The results obtained suggest 
that the iodine atom in the benzene ring is interacting with those amino acids, enabling the access 
to the active site and increasing the binding, resulting in a more potent compound.  
Moreover, taking into account the hypothesis proposed by J.Lee et al. that normal but not 
transformed cells repair DNA damage upon removal of HDACi, a long-term binding could  
increase the toxicity of the compound. That could explain the high toxicity showed by 16c towards 
HDF cells.  
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IV. CONCLUSIONS 
 
In this work, 30 analogues of HDACi approved drugs (SAHA and Belinostat) were 
successfully synthesized and evaluated as anticancer agents in breast (MCF-7) and lung (H460) 
cancer cell lines.  
None of the carboxylic acids tested showed a decrease in cell viability in any of the 
concentrations tested, in both MCF-7 and H460 cells.  
Cells treated with the hydroxamic acids synthesized presented a decrease in cell viability 
and this effect was higher with substitution in the benzene ring in an ortho position, especially 
with iodine and with bigger linker sizes. 
Synthesized compound hydroxy-N'-(4-iodophenyl)octanediamide (16c) had a cytotoxic 
effect in cancer cells approximately twofold higher that SAHA even at the lowest concentration 
tested (5 µM). Furthermore, preliminary results showed that 16c was able to induce apoptosis 
and cell cycle arrest at the G2/M phase of the cell cycle in the MCF-7 breast cancer cell line. 
 
An important characteristic of HDACi is that they induce cancer cell death at 
concentrations to which normal cells are relatively resistant, making them well suited for cancer 
therapy. However, compound 16c showed an effect on cell viability also in HFS. In the future, 
generation of dose-response curves of compound 16c will be required, to evaluate the potency 
of the compound in cancer cells and normal cell resistance, and evaluate if these cells present 
different sensitivities to compound toxicity at lower concentrations.   
 
HDACi action leads to differences in histone acetylation levels that can be measured by 
western blotting using antibodies for acetylated histones. In future work, it is important to use this 
technique in order to assess if compound 16c is able to increase histone acetylation levels.  
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VI. APPENDIX 
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Figure III.26 - Standard curves obtained for each cells (MCF-7, H460 and HDF) for PrestoBlue Cell Viability 
Assay.  See section II.2.3 
